Latest / Psychology In Seattle Podcast / Psychedelic Assisted Therapy (2020 Rerun)
Transcript
- 0:00Speaker 1: Hey, deserving listeners. I get a lot of questions from
- 0:03Speaker 1: you asking about using psychedelics, using LSD, microdosing, psilocybin, this
- 0:10Speaker 1: kind of thing in therapeutic work, and although I usually
- 0:17Speaker 1: like to answer such questions, it's not my area of expertise.
- 0:20Speaker 1: I can look at the research, I can look at
- 0:22Speaker 1: the literature and you know, sort of digest it and
- 0:26Speaker 1: communicate it to you, but you know that can only
- 0:28Speaker 1: go so far. So I thought I would have a
- 0:31Speaker 1: expert on the podcast, Elizabeth Nielsen, to talk about this
- 0:35Speaker 1: topic since so many people have so many questions about it.
- 0:39Speaker 2: Welcome to the podcast, Elizabeth.
- 0:41Speaker 3: Thank thank you so much.
- 0:43Speaker 1: So can you introduce yourself to the podcast listeners please?
- 0:47Speaker 3: Yeah. Absolutely. My name is Elizabeth Nielsen. I'm a psychologist.
- 0:52Speaker 3: I'm based in New York City and I do a
- 0:55Speaker 3: couple of things in my professional work. I have worked
- 0:59Speaker 3: for about six years now on clinical trials of psychedelic
- 1:04Speaker 3: assisted treatments. Those are FDA approved trials taking place at
- 1:10Speaker 3: major institutions. I've worked on trials of psilocybin for alcohol
- 1:14Speaker 3: use disorder, trials of psilocybin for treatment resistant depression, as
- 1:20Speaker 3: well as trials of m d m A for post
- 1:23Speaker 3: traumatic stress disorder. So I've got a fairly big background
- 1:27Speaker 3: in terms of providing therapy and research trials and also
- 1:34Speaker 3: training other therapists to do that work. And then outside
- 1:37Speaker 3: of that work in private practice, I also work with people, clients, patients,
- 1:44Speaker 3: the public to address some harm reduction issues around psychedelic
- 1:49Speaker 3: use and other settings, as well as help clinicians get
- 1:53Speaker 3: educated about what's going on in the field of psychedelic
- 1:55Speaker 3: research and how they can have conversations with their clients
- 1:59Speaker 3: about their decisions to use psychedelics or not use psychedelics,
- 2:04Speaker 3: or what those experiences might have been like. So I'm
- 2:07Speaker 3: doing a variety of things, and I'm hopeful that I
- 2:09Speaker 3: can be here and maybe answer some questions and shed
- 2:13Speaker 3: some light on some of the mysteries around this field.
- 2:16Speaker 3: I am here just sort of representing myself, my own
- 2:19Speaker 3: my own private practice work. Although I have a lengthly
- 2:22Speaker 3: history in the research studies, I'm I'm not representing any
- 2:26Speaker 3: specific institution or talking on behalf of the study at
- 2:28Speaker 3: this point.
- 2:30Speaker 1: So how can psychedelics be used therapeutically? You mentioned treatment
- 2:36Speaker 1: resistant depression PTSD addiction. You know some of our listeners
- 2:42Speaker 1: struggle with these things and might be excited to hear
- 2:45Speaker 1: about alternatives or other methods to treating those conditions.
- 2:50Speaker 3: Absolutely, I mean, I think there's there's in general a
- 2:53Speaker 3: lot of excitement about that. What people may not be
- 2:57Speaker 3: so aware of is that there was actually a fairly
- 3:00Speaker 3: strong body of research and literature on the use of psychedelics,
- 3:06Speaker 3: specifically mostly LSD, dating back from the nineteen fifties and
- 3:12Speaker 3: nineteen sixties and early seventies, before the current climate of
- 3:17Speaker 3: restrictions were put into place, and so a lot of
- 3:22Speaker 3: research was done. A lot of a lot of people
- 3:26Speaker 3: receive these treatments in experimental settings and research settings, but
- 3:30Speaker 3: these drugs are never approved for therapeutic use in the
- 3:33Speaker 3: way that people are attempting to get them approved now.
- 3:38Speaker 3: So more recently, what we're seeing is some small pilot
- 3:41Speaker 3: studies that are giving the initial indication that it may
- 3:45Speaker 3: be feasible to use psychedelics in a therapeutic setting, so
- 3:49Speaker 3: in combination with preparatory and integrative psychotherapy in treatment. But
- 3:55Speaker 3: what I really want to emphasize is that those when
- 3:59Speaker 3: those medicines are used in that way, it's distinct from
- 4:04Speaker 3: use in any other setting. So there's this whole psychotherapy
- 4:08Speaker 3: container that goes on around it as well as it's
- 4:12Speaker 3: very experimental at this point, I mean where the research
- 4:16Speaker 3: is really in its beginning stages, and the data to
- 4:19Speaker 3: demonstrate actual actual efficacy or actually who this might be
- 4:24Speaker 3: helpful for and which indications is just still in the
- 4:28Speaker 3: process of being gathered right now.
- 4:30Speaker 2: So what have you seen in your practice?
- 4:32Speaker 1: Do you actually use these methods with your clients?
- 4:36Speaker 3: Well, I do in research settings, and there's there are
- 4:40Speaker 3: some great publications that address the way that those research
- 4:46Speaker 3: settings psychotherapies are are carried out. I can talk a
- 4:51Speaker 3: little bit about some of the structures of them. For instance,
- 4:55Speaker 3: in in research with alcohol use disorder, people are given
- 5:00Speaker 3: preparatory psychotherapy sessions, They're given some actual counseling around changing drinking,
- 5:09Speaker 3: and then they're given the psychedelic session with the support
- 5:13Speaker 3: of two psychotherapists that have worked with them before and
- 5:17Speaker 3: stay with them through the entire session, and then they
- 5:20Speaker 3: have a couple of follow up integrative psychotherapy sessions to
- 5:24Speaker 3: help really consolidate those gains. And we call that integration,
- 5:28Speaker 3: and it's designed to help people really build the insights
- 5:34Speaker 3: and knowledge that they may have discovered during the psychedelic
- 5:37Speaker 3: session into the course of their daily life, so to
- 5:41Speaker 3: really take action based on the things that they may
- 5:44Speaker 3: have experienced or learned during their experience.
- 5:47Speaker 1: Yeah, from what I understand, and correct me if I'm wrong.
- 5:49Speaker 1: The protocol is that someone signs up for the study
- 5:54Speaker 1: and they're saying, yeah, I suffer from ongoing addiction issues
- 5:59Speaker 1: and I've tried various different things to stop and I'm
- 6:03Speaker 1: I wanted, you know, I want to try this other method.
- 6:06Speaker 2: And they will have a talk about, you know.
- 6:12Speaker 1: Their history of psychedelics maybe, but they also talk about
- 6:17Speaker 1: with a professional expert about what the psychedelics session session
- 6:21Speaker 1: is going to be like and what you know to expect,
- 6:25Speaker 1: so that they don't have a bad trip, as they say,
- 6:30Speaker 1: And then you administer the psychedelic the LSD usually, and
- 6:37Speaker 1: then they will have their experience and there's someone there
- 6:44Speaker 1: with them.
- 6:45Speaker 2: As you say, you said, there's two people with them, correct.
- 6:48Speaker 3: Yeah, By and large, research protocols are using two very
- 6:52Speaker 3: specifically highly trained therapists that sit with the UH with
- 6:57Speaker 3: the participant for the entire eight hour session.
- 7:00Speaker 1: Yeah, and talking with them, making sure they don't have
- 7:03Speaker 1: a bad trip, that kind of thing, and also helping
- 7:07Speaker 1: them to maybe explore is it kind of free associative
- 7:11Speaker 1: for the participant or are there specific protocol questions they ask, Well, it.
- 7:16Speaker 3: Depends a little bit on the protocol. So first of all,
- 7:19Speaker 3: I want to just go back and write one thing,
- 7:22Speaker 3: which is that we're not actually using LSD in any
- 7:25Speaker 3: of the trials in the United States at this point,
- 7:28Speaker 3: trials are being conducted with psilocybin, which, for listeners who
- 7:32Speaker 3: may be unfamiliar, is chemically and experientially similar to LSD,
- 7:37Speaker 3: but it's shorter acting. It's actually the naturally occurring compound
- 7:42Speaker 3: found in what's commonly known as magic mushrooms, although what
- 7:45Speaker 3: we use in research settings is pure medical grade psilocybin.
- 7:52Speaker 3: But to answer your question about the actual sessions, you know,
- 7:56Speaker 3: there are different approaches. For the most part, people are
- 8:01Speaker 3: asked to sort of focus on their internal experience, and uh,
- 8:06Speaker 3: researchers or people conducting sessions are using I shades and
- 8:11Speaker 3: headphones and sitting with the participant, but really attempting to
- 8:17Speaker 3: allow them to take off into their own internal landscape
- 8:20Speaker 3: and go exploring to the extent that they're that they're
- 8:24Speaker 3: able to let go of being involved in what's going
- 8:29Speaker 3: on outside of them in the room in conversation with
- 8:33Speaker 3: the therapists, but actually diving into that, into those internal workings.
- 8:38Speaker 3: Now you mentioned also bad trips, and that's a very
- 8:43Speaker 3: sort of colloquial term for often a combination of you know,
- 8:47Speaker 3: sort of overwhelming experiences, maybe some fear, maybe some panic,
- 8:52Speaker 3: and really in research, we've we've found that we're we're
- 8:56Speaker 3: preparing people to you know, as best we can to
- 8:59Speaker 3: be open to and accept whatever experience arises. We're doing
- 9:04Speaker 3: a lot of things to reassure and reduce fear. We're
- 9:08Speaker 3: also you know, giving this in a research medical setting,
- 9:12Speaker 3: so some of the some of the factors that might
- 9:15Speaker 3: be scary for people in other settings or you know,
- 9:17Speaker 3: are not present. Right, it's completely legal, there's medical monitoring,
- 9:22Speaker 3: all that stuff is in place. People are very well
- 9:24Speaker 3: screened for any health counter indication. But we do recognize that,
- 9:32Speaker 3: you know, sometimes people have some difficult experiences and those
- 9:36Speaker 3: if they're sort of approached with a sense of openness
- 9:39Speaker 3: and curiosity, can actually lead to some really fruitful learning
- 9:43Speaker 3: and really fruitful experiences. So I think it's a little
- 9:47Speaker 3: bit of a balancing act there.
- 9:48Speaker 1: So then after the session there's a follow up soon after.
- 9:55Speaker 3: Yeah, people come back. In general, in research protocols, people
- 9:59Speaker 3: come back and have a integration session, a non drug
- 10:03Speaker 3: psychotherapy session, if you will, the following day again with
- 10:07Speaker 3: the same two therapists, and depending on the you know,
- 10:11Speaker 3: the target diagnosis and the problem and why they're there,
- 10:15Speaker 3: and a little bit on what the protocol is, that
- 10:18Speaker 3: discussion can be a place to talk about what occurred
- 10:22Speaker 3: during the psychedelic session as well as how that might
- 10:26Speaker 3: translate into what's happening for them in terms of broader
- 10:30Speaker 3: change in.
- 10:30Speaker 1: Their life and the target conditions. We've been saying addiction,
- 10:36Speaker 1: but this is a similar protocol for PTSD and depression.
- 10:39Speaker 3: There are a lot of there are a lot of
- 10:41Speaker 3: similarities in overlap. But you know, when you're working with
- 10:45Speaker 3: diagnosis specific protocols, those are always going to be slightly
- 10:50Speaker 3: tailored to that population. But a lot of the procedures
- 10:54Speaker 3: are a lot of the sort of general procedures that
- 10:57Speaker 3: we're discussing now are fairly similar, and you see these
- 11:01Speaker 3: published in you know, for instance, the alcohol trial protocol
- 11:07Speaker 3: has been well described in the literature. UH the nd
- 11:12Speaker 3: M A for post Traumatic stress disorder UH Therapy Manual
- 11:17Speaker 3: is actually available online. Those studies are sponsored by a
- 11:20Speaker 3: group called MAPS, the Multidisciplinary Association for Psychedelic Studies. Their
- 11:25Speaker 3: website is MAPS dot org and there's a lot of
- 11:28Speaker 3: resources there for people whom I want to read more
- 11:30Speaker 3: about this, uh, this protocol and treatment approach.
- 11:33Speaker 1: So I'm imagining and I could be wrong about this.
- 11:36Speaker 1: That the follow up session, and maybe even during the
- 11:39Speaker 1: psychedelic session, there are questions about like if the participant
- 11:46Speaker 1: is thinking, Okay, I want to work on my alcohol addiction,
- 11:50Speaker 1: and so there might be uh, you know, soft open
- 11:55Speaker 1: ended questions during and after around like so you know,
- 12:00Speaker 1: what was your experience and how do you think it
- 12:03Speaker 1: relates to maybe the underlying reasons why you are, you know,
- 12:10Speaker 1: compulsively drinking or what kinds of discoveries did you make?
- 12:15Speaker 1: And then okay, how does that relate to your behavior?
- 12:21Speaker 1: But that's just me supposing what kind of questions or
- 12:24Speaker 1: discussions are happening during those times.
- 12:26Speaker 3: For the most part, those discussions would be happening after
- 12:28Speaker 3: the session. The model for psychedelic assisted therapy is actually
- 12:34Speaker 3: to set up the relationship with the participant in such
- 12:38Speaker 3: a way that they are able to really dive into
- 12:42Speaker 3: having their own complete experience without much interference from the
- 12:46Speaker 3: therapist during the experience. Now, of course we're there if
- 12:51Speaker 3: someone needs to talk, they're having an emotional time, they
- 12:55Speaker 3: need some reassurance, some assistance. But the model of psychedelic
- 13:01Speaker 3: assistic therapy is really to allow people to kind of
- 13:05Speaker 3: have their own profound experience that then can be discussed
- 13:09Speaker 3: and integrated later. There's another model that people may be
- 13:13Speaker 3: less familiar with, which is called psycholytic therapy, where usually
- 13:18Speaker 3: lower doses would have been used to help people be
- 13:23Speaker 3: able to have a more open frame of mind, perhaps
- 13:28Speaker 3: some changes in perception and cognition, but really to be
- 13:33Speaker 3: able to engage in psychotherapy during the active acute psychedelic
- 13:38Speaker 3: drug effects. And that model was used and tested during
- 13:43Speaker 3: the nineteen fifties and sixties. It was developed at that
- 13:46Speaker 3: time and it was put into practice. But that, for
- 13:50Speaker 3: the most part, is less of what we're doing now.
- 13:54Speaker 3: We're really usually focusing on allowing people to have that
- 13:58Speaker 3: full psychedelics experience and then bringing it back and discussing
- 14:02Speaker 3: it later.
- 14:03Speaker 1: Yeah, So I'm trying to imagine what it would be
- 14:06Speaker 1: like or what a possible result of this would be
- 14:10Speaker 1: like for someone and I'm thinking like afterwards, they are thinking.
- 14:16Speaker 1: You know, it's not uncommon. I've heard it from a
- 14:20Speaker 1: lot of people just recreationally their experiences with psychedelics, and
- 14:26Speaker 1: they'll say things like, well, I just opened up this
- 14:31Speaker 1: whole new way of looking at the world and myself,
- 14:33Speaker 1: and I carry it with me now. You know, There'll
- 14:37Speaker 1: be people that will say, I only used LSD three
- 14:41Speaker 1: times and it was ten years ago, and I still
- 14:43Speaker 1: carry those wisdoms with me to help me in my life.
- 14:48Speaker 1: It helps me to see that I'm connected to the
- 14:52Speaker 1: universe in a way that isn't always intuitive, or it
- 14:56Speaker 1: makes me realize that there's a higher purpose best to everything,
- 15:01Speaker 1: and I don't need to worry quite as much about
- 15:04Speaker 1: the day to day things, which and that worry is
- 15:07Speaker 1: what led me to be, you know, having mental illness
- 15:11Speaker 1: symptoms or addiction compulsions. And with that wisdom, one I
- 15:20Speaker 1: can allow myself to occasionally have a drink or two.
- 15:24Speaker 1: I am not stressed out to the point where I
- 15:27Speaker 1: need a drink. Are these the kinds of things that
- 15:29Speaker 1: people are saying, I mean, just as one micro example.
- 15:32Speaker 3: So I think it may be actually hopeful here to
- 15:35Speaker 3: shift into talking about working with people who have had
- 15:38Speaker 3: experiences outside of the research, which is something that I
- 15:42Speaker 3: do in private practice and have worked on developing a
- 15:46Speaker 3: training program for therapists to learn also how to be
- 15:50Speaker 3: able to do because we do know that a large,
- 15:54Speaker 3: fairly decent percentage of people it's been quoted as somewhere
- 15:58Speaker 3: around ten percent of the population United States, have had
- 16:01Speaker 3: experiences with psychedelics, and many of those people, you know,
- 16:07Speaker 3: may come into therapy and have something like what you described,
- 16:11Speaker 3: and you know, would like to be able to discuss
- 16:14Speaker 3: it or maybe feel that they've learned something really valuable
- 16:17Speaker 3: from it. So that's that's a known phenomenon. I mean,
- 16:21Speaker 3: our position is really that you know, from a harm
- 16:25Speaker 3: reduction standpoint, there is a reason to be able to
- 16:30Speaker 3: be curious about those experiences and bring those experiences into
- 16:33Speaker 3: psychotherapy should someone want to.
- 16:37Speaker 1: Yeah, but I'm still making a lot of assumptions, and
- 16:41Speaker 1: I'd rather have you tell me what the research is
- 16:45Speaker 1: finding in terms of with the participants, what are they
- 16:50Speaker 1: saying is I don't know the design of the research
- 16:54Speaker 1: that you're referring to, but the research that I would
- 16:58Speaker 1: come across there trying to reduce symptoms they're trying to
- 17:02Speaker 1: see does this protocol actually reduce the symptom the target symptom,
- 17:06Speaker 1: And of course it's hard to know why that's happening.
- 17:11Speaker 3: But tell you that the large scale compared to comparison
- 17:17Speaker 3: studies like large, larger scale placebo double blind trials, by
- 17:24Speaker 3: and large, are not they're not finished yet. They're not
- 17:27Speaker 3: they haven't been done yet. What we're really looking at
- 17:29Speaker 3: is results from small scale pilot studies. So for instance,
- 17:35Speaker 3: pilot studies where you know, ten people came through the protocol,
- 17:38Speaker 3: everybody got open label psilocybin, and by and large, we
- 17:43Speaker 3: did see vast improvement. There was a publication of that
- 17:47Speaker 3: a couple of years ago that I've spoken about at
- 17:50Speaker 3: several conferences. And we do see reductions in drinking, We
- 17:53Speaker 3: do see reductions in both heavy drinking and overall drinking days.
- 17:58Speaker 3: We do see, you know, across the board, very positive outcomes.
- 18:04Speaker 3: But those aren't large scale comparison studies, they're not double blind.
- 18:09Speaker 3: We don't know how much of that is placebo effect,
- 18:13Speaker 3: and those sorts of things, or how much of that
- 18:15Speaker 3: is would also be accounted for by placebo effect if
- 18:19Speaker 3: somebody ran the whole protocol exactly the same but without
- 18:22Speaker 3: the psilocybet. That's what's actually being tested right now. So
- 18:25Speaker 3: this research is really and it's and it's kind of
- 18:27Speaker 3: in its infancy. There are some a couple of great
- 18:32Speaker 3: qualitative publications where people have talked about their experience, and
- 18:38Speaker 3: you know, the profundity of the insight is really astounding
- 18:45Speaker 3: from my own observations and from reading a lot of
- 18:49Speaker 3: these these reports and transcriptions things that I've that I've
- 18:55Speaker 3: worked through and published on. You know, people are really
- 18:58Speaker 3: feeling a profound shift in their internal state, their internal
- 19:02Speaker 3: relationship to their drinking, and that is, you know, related
- 19:09Speaker 3: to the change that they're feeling. But we don't really
- 19:12Speaker 3: we don't really have such solid data as far as
- 19:16Speaker 3: exactly what kinds of experiences people need to have or
- 19:21Speaker 3: to what extent the subjective experience is, you know, how
- 19:26Speaker 3: it's exactly translating into change. I think that's it'll be
- 19:31Speaker 3: great to be investigating that for the next thirty forty
- 19:34Speaker 3: years at least. But that's really it's very beginning of
- 19:37Speaker 3: our understanding.
- 19:39Speaker 1: Yeah, and I appreciate your tentative scientific responses that you
- 19:44Speaker 1: know tells me that you're a responsible science communicator and
- 19:50Speaker 1: it's helpful, I think for people to hear this conversation
- 19:55Speaker 1: and the way that you're communicating about it, partially because
- 20:00Speaker 1: there's so much hype around this right now. A lot
- 20:03Speaker 1: of people on the Internet are saying, like there are
- 20:06Speaker 1: are even news articles with titles like, you know, magic
- 20:11Speaker 1: mushrooms cures addiction. You know, scientists prove that LSD can
- 20:16Speaker 1: cure your PTSD. And when I would see these these claims,
- 20:22Speaker 1: I was skeptical, obviously, because that's a pretty fantastical claim
- 20:27Speaker 1: and if true, it can just completely rework our entire
- 20:31Speaker 1: understanding of the mind and also of our of our
- 20:34Speaker 1: industry to be great. And when I looked into the research,
- 20:36Speaker 1: I found right it would be these small pilot studies.
- 20:40Speaker 1: I mean, partially because the government has been suppressing these
- 20:44Speaker 1: kinds of research investigations, legal reasons, funding reasons, and so
- 20:51Speaker 1: we're essentially back in the fifties with regards to our
- 20:56Speaker 1: you know, data gathering. We have tons of data on prozac,
- 21:01Speaker 1: but not a lot of ton not a lot of
- 21:04Speaker 1: data on this yet. And you're, you know, you're saying, well,
- 21:07Speaker 1: we just have to be careful about any broad claims
- 21:10Speaker 1: we make. We need bigger studies. We need more time.
- 21:13Speaker 1: It might take thirty forty years for.
- 21:14Speaker 2: Us to know.
- 21:16Speaker 1: And so a lot of my response to people when
- 21:19Speaker 1: they would ask me questions, I upon the you know,
- 21:25Speaker 1: a little bit of investigation that I did, I came
- 21:28Speaker 1: to the conclusion of, like, well, we just don't know yet.
- 21:30Speaker 1: Is it is it possible that these substances can help
- 21:36Speaker 1: some people? It seems highly likely because one the data
- 21:41Speaker 1: seems to be pointing in that direction. And also it
- 21:45Speaker 1: stands to reason. I mean, you know a lot of
- 21:47Speaker 1: people like these drugs for probably some logical reasons, and
- 21:52Speaker 1: and so it's it's stands the reason that you know,
- 21:56Speaker 1: it's like if somehow caffeine was illegal or something, and
- 22:00Speaker 1: and we were you know, these speculations like I wonder
- 22:05Speaker 1: if caffeine helps me work better when I'm at when
- 22:08Speaker 1: I'm at the office, And it's like, yeah, I mean,
- 22:11Speaker 1: it stands to reason if people are using alcohol caffeine
- 22:15Speaker 1: to you know, keep them on task at work recreationally,
- 22:20Speaker 1: It's like it's probably likely that there's some effect there.
- 22:23Speaker 2: It's hard to know.
- 22:24Speaker 1: And you're also careful to say, look, you know, we
- 22:27Speaker 1: don't have double blinded studies, you know, the placebo effect
- 22:31Speaker 1: is real, right, and there's just countless examples of of that,
- 22:37Speaker 1: and and but I'm curious how one could double blind it,
- 22:40Speaker 1: because you would have to give people a psychedelic experience
- 22:44Speaker 1: without having administered the substance, you know, because usually with
- 22:49Speaker 1: you know, other kinds of you know, when they do
- 22:52Speaker 1: trials of say prozac, you give them a pill. But
- 22:55Speaker 1: there's no immediate, intoxicating, noticeable effect from from taking prozac,
- 23:02Speaker 1: for example, and that can't be reproduced in a control
- 23:08Speaker 1: So how would you really truly eliminate the placebo effect
- 23:12Speaker 1: or of control for it.
- 23:13Speaker 3: I think of the studies that are doing placebo controlled
- 23:17Speaker 3: work as doing it's more like therapy only condition, or
- 23:22Speaker 3: therapy plus psychedelic condition, if you will. So people are
- 23:27Speaker 3: still getting all of the psychotherapy, they're getting the session
- 23:31Speaker 3: just the way they would They're getting you know, a
- 23:37Speaker 3: placebo pill whatever it is for the session. Some studies
- 23:41Speaker 3: using active placebo, some use an inert placebo. But just
- 23:46Speaker 3: the process. The amazing is just the process of going
- 23:48Speaker 3: through all of that preparation and going through that session
- 23:52Speaker 3: where they're coming into the room and they're lying down
- 23:55Speaker 3: and putting on these ice sheades and headphones and they're
- 23:57Speaker 3: sort of disconnected from the inner net and all of
- 24:00Speaker 3: their usual things that you know, remind them who they are.
- 24:07Speaker 3: That in itself can can be a powerful experience. And
- 24:13Speaker 3: you know, people have been known to be unsure of
- 24:16Speaker 3: what they got, and therapist as well can have been
- 24:21Speaker 3: known to be unable to tell. I can tell you
- 24:24Speaker 3: anecdotally from my own experience, I'm not always sure if
- 24:28Speaker 3: someone got a placebo or an active dose, so a
- 24:30Speaker 3: psychedelic in a study, the situation is strange and unique
- 24:35Speaker 3: enough that it it is genuinely not always clear.
- 24:43Speaker 2: Yeah, okay, that makes sense.
- 24:45Speaker 1: Like a deprivation chamber with a you know, two people
- 24:49Speaker 1: there with you.
- 24:51Speaker 2: So what is that like?
- 24:52Speaker 1: I mean eight hours, do you take a break at
- 24:54Speaker 1: some point to go to the bathroom.
- 24:56Speaker 3: We definitely take a bathroom break. We definitely get up
- 24:59Speaker 3: and have a stretch, you know, a quick lunch or
- 25:03Speaker 3: a walk around a block. But no, really, the two
- 25:08Speaker 3: therapists are dedicated to being there for the day in
- 25:10Speaker 3: the room with the person. Someone one of us at
- 25:13Speaker 3: least is always present there. We never have both people
- 25:17Speaker 3: out of the room for any period of time. And
- 25:23Speaker 3: that is not just to ensure physical safety, but really
- 25:26Speaker 3: to ensure the psychological safety that the patient knows that
- 25:29Speaker 3: they're always there. Uh, Someone's always there to care for them.
- 25:32Speaker 3: Someone's always there to assist them, to bring them water,
- 25:35Speaker 3: to help them if they need to go to the bathroom,
- 25:37Speaker 3: whatever it is. They're never left alone.
- 25:44Speaker 1: In the rare case where someone does have a significant
- 25:49Speaker 1: fear response, what do you do.
- 25:51Speaker 3: We're really highly trained in how to provide assurance and
- 25:56Speaker 3: assistance and verbal you know, verbal interaction with a person
- 26:02Speaker 3: in a way that can help them move in and
- 26:05Speaker 3: through those experiences. So it's really important that we have
- 26:12Speaker 3: a good, strong relationship with them to begin with. We
- 26:18Speaker 3: touch on certain topics before the session, such as you know,
- 26:24Speaker 3: potential effects and things that they may feel, and we
- 26:26Speaker 3: can we can remind people of those things. We can
- 26:31Speaker 3: help them to get a little bit more oriented or
- 26:34Speaker 3: to maybe lessen the intensity of the experience by adjusting
- 26:39Speaker 3: certain things in the room. And we can you know,
- 26:44Speaker 3: also be just present to sit with someone as they
- 26:48Speaker 3: go through a difficult experience so that they're not with
- 26:51Speaker 3: that difficult experience alone. And those are the sorts of
- 26:54Speaker 3: things that I think allow people to have those experiences
- 26:59Speaker 3: and let them be something that becomes part of the
- 27:03Speaker 3: larger picture and something that they may actually find some
- 27:07Speaker 3: insight in towards the end, as opposed to be sort
- 27:10Speaker 3: of stuck in this very fearful or distressing place. Yeah.
- 27:15Speaker 1: I'm just imagining from my own experience with people who
- 27:18Speaker 1: are tripping recreationally. It's like they, you know, there's so
- 27:24Speaker 1: many different experiences someone to have, but they might be
- 27:27Speaker 1: like sitting in a dark room or something and it's like.
- 27:32Speaker 2: I'm falling into a pit.
- 27:33Speaker 1: I'm falling into it, or a giant you know, bloody
- 27:39Speaker 1: you know, mouth is eating me my leg or whatever
- 27:42Speaker 1: they say, and you're just like, okay, I'm here, You're okay,
- 27:47Speaker 1: that's not actually happening. That's what you're seeing. Do you
- 27:50Speaker 1: do you want to turn on the lights a little bit?
- 27:52Speaker 1: Do you do you want to turn off the music?
- 27:54Speaker 1: Do you you know, You're okay? Everything fine, You're not alone.
- 28:01Speaker 1: I'm here with you.
- 28:03Speaker 3: Uh.
- 28:04Speaker 2: And that can often help people, is it? That kind
- 28:06Speaker 2: of stuff?
- 28:07Speaker 3: Right? So what you're what you're sitting I think is
- 28:11Speaker 3: similar in that people who have some training in psychedelic
- 28:17Speaker 3: harm reduction, for instance, for festival settings or peer settings
- 28:21Speaker 3: or things like that may know some some helpful things
- 28:24Speaker 3: that they could do to see someone through a difficult experience.
- 28:29Speaker 3: And I'll refer again to MAPS because they have an
- 28:31Speaker 3: excellent training for people that want to learn how to
- 28:35Speaker 3: do psychedelic harm reduction, especially in festival settings. It's called
- 28:38Speaker 3: the Zendo Project, and that's also a manual that's available
- 28:42Speaker 3: on their on their website for free. But it's different
- 28:48Speaker 3: in that if you're in a peer setting or a
- 28:51Speaker 3: festival setting or another setting, you know, there may not
- 28:54Speaker 3: be somebody who's there who has that expertise in that
- 28:58Speaker 3: training and who is you know, sober and dedicated to
- 29:03Speaker 3: assisting you through it. And in the research settings, you know,
- 29:07Speaker 3: that's really a guarantee, it's really a given. Your therapists
- 29:10Speaker 3: are there specifically to help the person, and not only
- 29:14Speaker 3: with what they can do, but there are of course
- 29:17Speaker 3: a whole host of other uh you know, staff and
- 29:22Speaker 3: support that that could be access if needed.
- 29:25Speaker 1: This is just you, This is just me asking you
- 29:27Speaker 1: to speculate, and I don't know how comfortable you are
- 29:29Speaker 1: with that, but uh, because I would imagine some researchers
- 29:33Speaker 1: would be like, well, okay, maybe I sometimes allow myself
- 29:37Speaker 1: to speculate, but I certainly I'm not going to go
- 29:40Speaker 1: on public record because that would make me people would
- 29:45Speaker 1: be suspicious of me, you know, routing the data and
- 29:48Speaker 1: my speculative direction. But if you're comfortable, Uh, why do
- 29:53Speaker 1: you think this works?
- 29:54Speaker 3: Ah, well, that is a great question. I can cite
- 29:57Speaker 3: a couple of potential out and again I can say,
- 30:02Speaker 3: you know, it could be any or all or some
- 30:05Speaker 3: combination of these things. But these are some of the
- 30:08Speaker 3: things that are already talked about in the literature. So uh,
- 30:13Speaker 3: and there there is. You know, there is quite a
- 30:16Speaker 3: lot of quite a lot of writing about about this,
- 30:19Speaker 3: some of it comes out of that early research stage
- 30:21Speaker 3: and some of it coming in later. But for addictions, specifically,
- 30:27Speaker 3: when we're talking about classic psychedelics or serotonergic psychedelics such
- 30:31Speaker 3: as LSD and psilocybin, there are there is the potential
- 30:39Speaker 3: that pharmacologically those psychedelics can actually help correct or repair
- 30:46Speaker 3: some of the neurobiological changes that occur with long term
- 30:52Speaker 3: compulsive use of alcohol and other drugs and or be
- 30:58Speaker 3: somewhat of a protective fact pharmacologically. Now, the the neurobiological
- 31:05Speaker 3: end of this is not my main expertise, but population
- 31:10Speaker 3: studies and studies of groups such as UH syncretic churches
- 31:16Speaker 3: where a brew which is a sacrament which contains a
- 31:23Speaker 3: naturally occurring compound which is also in the same pharmacological class,
- 31:29Speaker 3: is consumed on a weekly or bi weekly basis by
- 31:32Speaker 3: a large population such as the entire congregation of the church.
- 31:38Speaker 3: People have actually studied the health outcomes for those groups
- 31:41Speaker 3: and demonstrated lower than would be expected rates of alcohol
- 31:47Speaker 3: abuse and other types of problems. So we know that
- 31:52Speaker 3: there may be some relationship there, just in terms of
- 31:55Speaker 3: drugs in that class having a protective factor or a
- 31:59Speaker 3: some sort of factor that reduces the tendency towards addictive problems.
- 32:04Speaker 1: Couldn't that also just be experiential. I mean, if they're
- 32:08Speaker 1: having a a group trip into the universe, the the
- 32:15Speaker 1: euphoria that one experiences can maybe hold them through the
- 32:21Speaker 1: difficulties of life where they don't have to turn to
- 32:23Speaker 1: substances to cope, do you know what I mean?
- 32:26Speaker 3: Potentially, But from the pharmacological level, I think that there
- 32:30Speaker 3: is actually reason to believe that those UH compounds in
- 32:35Speaker 3: that class are protective of developing or you know, help
- 32:42Speaker 3: help with healing from the damage done by compulsive alcohol use.
- 32:48Speaker 1: And then does that have to do with serotonin. I
- 32:50Speaker 1: mean that might be a simple question, but.
- 32:53Speaker 3: Yeah, yeah, it has. It has to do with how
- 32:58Speaker 3: the serotonin system gets regular over time with compulsive addictive behavior,
- 33:06Speaker 3: and how classic psychedelics can help in a corrective way
- 33:12Speaker 3: for that system. Okay, there's some research on this was
- 33:18Speaker 3: conducted by doctor Charlie Grobe who is at u c
- 33:22Speaker 3: l A. And if you look up something called the
- 33:25Speaker 3: host Gap Project, you'll find some some papers on that.
- 33:30Speaker 3: They actually went to visit groups that we're using these
- 33:34Speaker 3: medicines in a traditional context and did did not only interviews,
- 33:41Speaker 3: but actual biomarker measures to to determine this, uh, this
- 33:48Speaker 3: trend in this pattern. So that's been that's been fairly
- 33:52Speaker 3: fairly well established. Now, the other component of it is
- 33:56Speaker 3: if you look at things like, you know, the the
- 34:01Speaker 3: traditional approach to healing from addiction and the Tenets of
- 34:07Speaker 3: Alcoholics anonymous specifically, they talk about having a spiritual experience
- 34:13Speaker 3: as a key factor in healing from addiction, healing from alcoholism, right,
- 34:20Speaker 3: and some of the earliest research and some of the
- 34:24Speaker 3: most well established research, especially with psilocybin demonstrates that it
- 34:29Speaker 3: can occasion a mystical or mysticomi metic is a word
- 34:34Speaker 3: sometimes people use experience in a laboratory setting, when given
- 34:39Speaker 3: in the presence of supportive uh, supportive psychotherapists or supportive guides,
- 34:45Speaker 3: that is profound and lasting and on par with mystical
- 34:49Speaker 3: experiences that have been had in other contexts or for
- 34:53Speaker 3: other you know, engendered in other ways, such as through
- 34:56Speaker 3: prayer or through meditative experiences and things like that. So
- 35:04Speaker 3: it's possible that that subjective experience actually does contribute to
- 35:09Speaker 3: putting people on the path towards healing from addiction.
- 35:13Speaker 1: Yeah, okay, so those are the two main speculations or hypothesis.
- 35:18Speaker 3: Yeah, those are kind of two starter speculations. There are
- 35:22Speaker 3: definitely there are definitely a lot more, But I think
- 35:27Speaker 3: it's you know, I think I think in the end,
- 35:29Speaker 3: what we're going to be seeing is a variet like
- 35:33Speaker 3: a mix of different mechanisms of action, and that which
- 35:37Speaker 3: mechanisms are specifically the ones responsible for change in each
- 35:40Speaker 3: individual person will be somewhat of an individual profile for each.
- 35:44Speaker 1: Person, right, Yeah, I think that's the key, is that,
- 35:48Speaker 1: similar to other psychotropics, that it there's a set of
- 35:53Speaker 1: possibilities that might contribute to symptom change in an individual,
- 35:59Speaker 1: and it's unknown what set that individual is going to
- 36:03Speaker 1: you know, benefit from. And based on previous research, you know,
- 36:08Speaker 1: pretty solid or consensus understandings of serotonin. And it stands
- 36:14Speaker 1: to read that's why I, you know, when people were
- 36:16Speaker 1: kind of surprised that psychedelics were helping, I was like, well,
- 36:20Speaker 1: from my memory and from you know, biology classes and
- 36:24Speaker 1: psychotropic classes, I remember, you know, these psychedelics having something
- 36:29Speaker 1: to do with serotonin and other kinds of processes that
- 36:32Speaker 1: were similar to other over the or you know, prescribed
- 36:36Speaker 1: medications that are affecting the brain in a you know,
- 36:41Speaker 1: at least a related way. And so it makes sense
- 36:44Speaker 1: that psychedelics could either benefit in a similar way or
- 36:49Speaker 1: in a you know, related way. It's well known that
- 36:53Speaker 1: SSRIs can help with addiction, for example, and that involves
- 36:57Speaker 1: serotonin system in the brain, and so uh a a
- 37:03Speaker 1: sort of you know, uh controlled uh you know dose
- 37:10Speaker 1: if you will, of serotonin action in the brain might
- 37:14Speaker 1: have a similar effect for people. But it also stands
- 37:18Speaker 1: to reason, you know, the second speculation of uh, you know,
- 37:23Speaker 1: being connected to the universe is a profound experience and
- 37:26Speaker 1: hard to quantify, of course, but people will say, as
- 37:30Speaker 1: I was saying earlier, I tripped ten years ago at
- 37:34Speaker 1: burning Man and every you know, a few days, I
- 37:39Speaker 1: remember what happened that during the you know, that moment
- 37:43Speaker 1: for me, and.
- 37:43Speaker 2: It puts puts.
- 37:45Speaker 1: Things in perspective and really helps me. I'm you know,
- 37:48Speaker 1: I'm really glad that I went through that. I don't
- 37:52Speaker 1: want to do it all the time, but and you know,
- 37:54Speaker 1: maybe never again, but you know that that time, you know,
- 37:57Speaker 1: really helps me. Similar to I, you know, meditated for
- 38:02Speaker 1: a week in India and I carry that with me.
- 38:05Speaker 1: Or I climbed Mount McKinley and was looking out over
- 38:09Speaker 1: you know, the state and you know all the earth
- 38:14Speaker 1: I could see before me, or I the birth of
- 38:19Speaker 1: my child, or the I don't know, just various different
- 38:25Speaker 1: experiences that are uh well reported all the poets and
- 38:31Speaker 1: all the songwriters. Or I fell in love and that
- 38:33Speaker 1: redirected my life.
- 38:35Speaker 3: Absolutely. Yeah, the profundity of that experience really does. We
- 38:42Speaker 3: know from both the both research trials as well as
- 38:49Speaker 3: you know, uh survey data and follow up with people
- 38:52Speaker 3: who have had experiences in other settings, that it really
- 38:55Speaker 3: does stay with people and it really can be a
- 38:59Speaker 3: moment of pivot change.
- 39:01Speaker 2: Do the news headlines bother you?
- 39:03Speaker 3: No, But I think sometimes, as you alluded to before,
- 39:09Speaker 3: they can be they can be over generalizations, and they
- 39:15Speaker 3: can be a little bit misleading.
- 39:16Speaker 2: Yeah.
- 39:17Speaker 3: I'll often see people in private practice who are coming
- 39:21Speaker 3: in and uh, you know, seeking perhaps some uh, some
- 39:27Speaker 3: guidance around a decision to try a psychedelic in a
- 39:31Speaker 3: specific setting or maybe in a retreat setting or a
- 39:35Speaker 3: peer setting, And a lot of the conversation can be
- 39:41Speaker 3: around kind of mitigating the uh, the expectations that are
- 39:46Speaker 3: set up by press that is, you know, glowingly positive
- 39:53Speaker 3: but may not really capture the full picture of what
- 39:56Speaker 3: to expect or what's really going on or what the
- 40:00Speaker 3: risks may be.
- 40:01Speaker 1: The other symptom or condition that I see in the
- 40:06Speaker 1: research literature is around end of life and how psychedelics
- 40:10Speaker 1: are used to help people with their well being as
- 40:15Speaker 1: they prepare for death themselves. And they find for some
- 40:21Speaker 1: people they will after having one of these psychedelic treatment
- 40:27Speaker 1: sessions will be more at ease with the process of dying.
- 40:34Speaker 2: Do you have any familiar with that research?
- 40:36Speaker 3: Yes, And again that was research that initiated as a
- 40:43Speaker 3: potential indication in the nineteen fifties and sixties, and there
- 40:50Speaker 3: were some you know, there was some experimentation with classic psychedelics,
- 40:56Speaker 3: mostly LSD for that particular use. The research that was
- 41:00Speaker 3: conducted more recently, it was a study that was conducted
- 41:05Speaker 3: to sites at Johns, Hopkins and NYU was published in
- 41:09Speaker 3: twenty sixteen. And that research, it was actually a psychotherapy
- 41:16Speaker 3: study where they gave people psilocybin in the context of
- 41:22Speaker 3: psychotherapy that was designed to help address illicit and address
- 41:29Speaker 3: and discuss and integrate insights around end of life issues
- 41:36Speaker 3: or anxiety related to a cancer diagnosis. Was actually the
- 41:41Speaker 3: indication in that in that particular study. And again you know,
- 41:45Speaker 3: it was again a small pilot study, but the results
- 41:49Speaker 3: were the results were positive. I mean, people saw some
- 41:54Speaker 3: really profound positive changes. It's it's something to be cautious
- 41:59Speaker 3: about because it's not really enough or you know, results
- 42:04Speaker 3: of a long enough duration too, you know, to to
- 42:08Speaker 3: have an indication and an approval for that use. But
- 42:12Speaker 3: it certainly contributes to the pool of knowledge that we
- 42:15Speaker 3: have about this medicine and how it might be used
- 42:19Speaker 3: in order to help people that are that are suffering
- 42:22Speaker 3: in that way and my my sincere hope is that
- 42:26Speaker 3: the rest of the research that would be needed to
- 42:30Speaker 3: demonstrate that it could be used safely and reliably for
- 42:34Speaker 3: that particular in that particular way, can be conducted such
- 42:40Speaker 3: that it will become available because certainly, adding stress and
- 42:45Speaker 3: anxiety to an end of life care situation, when someone
- 42:50Speaker 3: is really struggling to cope with that, with that diagnosis
- 42:55Speaker 3: and that knowledge, it really really affects not just that
- 43:00Speaker 3: person's experience of of their own death, but the experience
- 43:05Speaker 3: I think of everyone around them, all of their family
- 43:07Speaker 3: and caregivers. And I think there's a great potential for
- 43:11Speaker 3: improving offerings for people in that situation.
- 43:15Speaker 1: Yeah, I completely agree. I really hope that. I mean,
- 43:21Speaker 1: one of the barriers is societal and governmental and political
- 43:26Speaker 1: cultural resistance to this, and it's ridiculous and that has
- 43:34Speaker 1: to stop. I suspect it will. Trends are heading in
- 43:37Speaker 1: that direction. Legalization of marijuana seems to be the you know,
- 43:43Speaker 1: at the sort for or at the chevron of movement
- 43:48Speaker 1: or more grown up understanding of these substances. You know,
- 43:51Speaker 1: we don't have to have a Nixonian idea of these substances,
- 43:55Speaker 1: and and it totally stands to reason, especially as more
- 44:01Speaker 1: people become atheistic. More people become atheists and don't believe
- 44:06Speaker 1: in an afterlife or don't believe in a god, you know,
- 44:11Speaker 1: where religion may have provided those experiences for people in
- 44:15Speaker 1: the past, it's harder to have that experience maybe for
- 44:20Speaker 1: some people. And so having this tool to connect people
- 44:28Speaker 1: with the universe, for lack of a better phrase, you know,
- 44:32Speaker 1: my it totally stands the reason. You know, you'll hear
- 44:36Speaker 1: people at whether end of life or not with a
- 44:40Speaker 1: having it, like I said, climbing Mount McKinley, or you know,
- 44:45Speaker 1: their child being born. These are profound experiences that psychology
- 44:50Speaker 1: often doesn't really focus on, you know, as a thing
- 44:54Speaker 1: to try to harness for the betterment of human beings.
- 45:00Speaker 1: And uh, and I think that psychedelics might be uh,
- 45:05Speaker 1: you know, involving that for for for a lot of people.
- 45:13Speaker 1: So what about when people are talking about microdosing, What
- 45:17Speaker 1: what's that all about?
- 45:18Speaker 3: Mm hmm. So microdosing is another area where I think
- 45:24Speaker 3: the perhaps the perception of what research exists or uh
- 45:30Speaker 3: the safety of that practice has been uh miss misestimated.
- 45:38Speaker 3: So we'll talk about that a little bit. Microdocing in
- 45:42Speaker 3: psychedelics refers to the practice of taking a small dose
- 45:46Speaker 3: of psychedelic usually about a tenth of an active or
- 45:50Speaker 3: full dose, and doing so on a either a daily
- 45:56Speaker 3: or every few days basis. You'll hear people say that
- 46:01Speaker 3: micro dosing is taking a sub perceptual dose. I think
- 46:07Speaker 3: a better word would be a sub psychedelic dose, or
- 46:11Speaker 3: a a dose that has some perceptible effect and as
- 46:18Speaker 3: far as change in mood or change in just body
- 46:22Speaker 3: feeling or sensation, things like that, maybe an energy level
- 46:27Speaker 3: or creativity, but that is not intoxicating or moving someone
- 46:34Speaker 3: into a space where they're uh, sort of disconnected from
- 46:39Speaker 3: their normal being able to conduct their normal routine, and
- 46:43Speaker 3: that dose is going to be you know, mean, different
- 46:45Speaker 3: things for different people. The practice of microdosing really came
- 46:51Speaker 3: to light and was initially I think documented and research
- 46:57Speaker 3: by psychologist by name of Jim Fadman who is based
- 47:02Speaker 3: in California, and he has recently well recently meaning the
- 47:08Speaker 3: last in this in this recent resurgence of of psychedelic research.
- 47:18Speaker 3: He's designed a way to study microdosing by essentially coming
- 47:24Speaker 3: up with a protocol for how often and what kinds
- 47:30Speaker 3: of things people might record about their microdosing experience and
- 47:33Speaker 3: allowing people to you know, self select and submit their
- 47:37Speaker 3: own data about their own experiences. And he's collected quite
- 47:41Speaker 3: a large body of literature and of sorry experiences and
- 47:48Speaker 3: has compiled and written and published and spoken about this
- 47:53Speaker 3: and it makes, you know, quite a compelling case for
- 47:57Speaker 3: the fact that this is something that's happening uh to
- 47:59Speaker 3: be documented and people are the people that are documenting
- 48:05Speaker 3: it and sending in these reports are really reporting some
- 48:09Speaker 3: some positive some positive changes. But what's really important to
- 48:14Speaker 3: remember about that is that it's self selecting, uh, not
- 48:19Speaker 3: blinded or so no placebo controlled uh studies. So it's
- 48:24Speaker 3: all self report data from people that are you know,
- 48:28Speaker 3: choosing to do this on their own and know that
- 48:29Speaker 3: they're doing it and doing it with the expectation of
- 48:32Speaker 3: a positive result. Right. But it is very interesting, I mean,
- 48:38Speaker 3: it's it's it's fascinating, and it's wonderful and really a
- 48:44Speaker 3: testament to his dedication to the field that he's been
- 48:47Speaker 3: able to gather so much documentation about about this practice.
- 48:54Speaker 3: There because of the fact that psychedelics are so closely
- 48:59Speaker 3: regulated controlled and right now the way things are for
- 49:03Speaker 3: research study, the therapists need to stay with people who
- 49:06Speaker 3: take psychedelics in the research setting for the duration of
- 49:09Speaker 3: eight hours after they take the psychedelic. There were there
- 49:15Speaker 3: aren't really studies where people are being given microdoses, uh,
- 49:20Speaker 3: you know, in a research setting and allowed to kind
- 49:24Speaker 3: of go out and go about their day and then
- 49:26Speaker 3: you know it's documented whether or not it's a placebo
- 49:29Speaker 3: or a microdose. That's that's not something that's that's happening.
- 49:32Speaker 3: I know that some people are trying to get something
- 49:34Speaker 3: like that off the ground, but because of the regulatory situation,
- 49:38Speaker 3: it's quite challenging. There is another study that's a very
- 49:43Speaker 3: interesting design is going on in Europe where people are
- 49:49Speaker 3: asked to basically self blind their own microdoses. So if
- 49:55Speaker 3: they're going to be microdosing, they're given a formula like
- 49:59Speaker 3: a a printable document where they can label their doses,
- 50:04Speaker 3: and they create their own placebo doses and their own
- 50:06Speaker 3: microt doses, and then they mix them all up and
- 50:08Speaker 3: there's a coded way that they're able to take a
- 50:12Speaker 3: random selection of those doses and this and report back
- 50:17Speaker 3: to the study which coded envelope they took, so that
- 50:21Speaker 3: the study knows which dose they took. On which day,
- 50:23Speaker 3: but the participant doesn't actually but again limited as in
- 50:29Speaker 3: people are supplying their own, their own actual psychedelics to
- 50:34Speaker 3: participate in the study, and so also you know, self
- 50:38Speaker 3: selecting as far as who's who's going to be doing that.
- 50:43Speaker 3: So those are some of the attempts to study this,
- 50:45Speaker 3: but we don't really know again what the long term
- 50:49Speaker 3: effects are, what the health effects are, or how this
- 50:52Speaker 3: would compare to, for instance, other interventions or traditional you know,
- 51:00Speaker 3: the use of traditional psychotropic meds.
- 51:03Speaker 1: Yeah, like I said, it stands to reason that this
- 51:06Speaker 1: would have some effect, however limited, and some benefit for
- 51:12Speaker 1: some people, however limited, and maybe you know, a moderate
- 51:15Speaker 1: amount of people could benefit moderately. Given that it involves
- 51:21Speaker 1: brain chemistry and that is at least akin to other demonstrated,
- 51:27Speaker 1: well researched psychotropics, it stands to reason that there would
- 51:31Speaker 1: be a signal there in the data. Having said that,
- 51:35Speaker 1: I'm old enough to remember various different hype around other
- 51:40Speaker 1: you know, magic pills. For example, Prozac I mentioned earlier,
- 51:44Speaker 1: I'm old enough to remember when that was considered to
- 51:49Speaker 1: be a miracle drug for all sorts of things, and
- 51:53Speaker 1: the headlines would state that people were you know, even
- 51:59Speaker 1: prescribers and scientists saw it that way. As we've gathered
- 52:04Speaker 1: more data over the past thirty years, this effect size
- 52:09Speaker 1: is getting smaller and smaller compared to placebo. And although
- 52:13Speaker 1: there's an effects size, there's a there's an effect for
- 52:16Speaker 1: some people. It certainly isn't the miracle drug that it
- 52:20Speaker 1: was seen as when it first hit the scene. And
- 52:25Speaker 1: I don't know if that's what psychedelics will experience in
- 52:28Speaker 1: terms of the data over the next thirty forty.
- 52:31Speaker 2: Years, but it certainly seems possible.
- 52:33Speaker 1: And obviously I have no idea, but I'm just when
- 52:39Speaker 1: I start hearing these headlines and I start hearing anecdot
- 52:42Speaker 1: because I remember people anecdotally talking about and I don't
- 52:46Speaker 1: doubt their experience, and I don't I'm not necessarily accusing
- 52:51Speaker 1: them of being subjected to a placebo effect. But it
- 52:55Speaker 1: just seemed like the rhetoric and among clinicians and among
- 52:59Speaker 1: scientists and among the media around prozac had had a
- 53:03Speaker 1: very similar beginning to the way psychedelics says and and
- 53:06Speaker 1: it also just seems like there's a certain amount of
- 53:09Speaker 1: people out there who just like the idea of psychedelics
- 53:12Speaker 1: as a regular part of their life or as a
- 53:16Speaker 1: as a nice thing, you know, for society or something.
- 53:19Speaker 1: And I just feel like there's and and you're you know,
- 53:23Speaker 1: very responsible in your language and your practice, and so
- 53:26Speaker 1: I I guess I just wanted to say that, do
- 53:30Speaker 1: you have any feelings about that?
- 53:31Speaker 3: Uh?
- 53:32Speaker 2: Rant, I just want to.
- 53:33Speaker 3: Yeah, well, it's it's a great rant, fantastic, well well done, Rant.
- 53:38Speaker 3: I mean I get that. I mean, I'm I am cautious,
- 53:42Speaker 3: and I'm certainly have my cautious hat on today because
- 53:47Speaker 3: the last thing that I want is for anyone your
- 53:50Speaker 3: listeners included in that category to uh to experience harm
- 53:55Speaker 3: because of this. And I think that there there is
- 53:59Speaker 3: certainly the potent for that. You know, the harms of
- 54:03Speaker 3: psychedelics are not the same kinds of harms that we
- 54:06Speaker 3: see in relation to you know, alcohol use and uh
- 54:11Speaker 3: obeits and you know maybe other uh maybe even other
- 54:16Speaker 3: psychotropic drugs that could have some really profound neurological problems
- 54:20Speaker 3: and things like that associated. But there really is a
- 54:23Speaker 3: potential for harm, especially with use in uncontrolled settings or
- 54:30Speaker 3: around people who may be unsafe uh and inexperienced, or
- 54:35Speaker 3: for people who have some real you know, psychological struggles
- 54:41Speaker 3: and difficulties for whom psychedelics can be a profoundly uh
- 54:47Speaker 3: just disorienting or uh dysregulating experience. So I, you know,
- 54:55Speaker 3: I I'm I'm also very optimistic about the research. I mean,
- 54:58Speaker 3: I I witnessing firsthand some of the really profound change
- 55:04Speaker 3: that is possible. But there's a lot that we don't
- 55:08Speaker 3: know about how to work with this and how to
- 55:10Speaker 3: really provide it to people in a way that's going
- 55:12Speaker 3: to be a consistently safe and therapeutic experience. And what
- 55:18Speaker 3: we're doing in the trials, really it doesn't translate to
- 55:22Speaker 3: other settings. You can't count on getting those same kind
- 55:25Speaker 3: of results in another setting. You know. It doesn't mean
- 55:29Speaker 3: that people don't have also some positive experiences and some
- 55:33Speaker 3: truly healing experiences in other settings, but they're not there's
- 55:39Speaker 3: they're they're not a guarantee, you know. There there's definitely, uh,
- 55:44Speaker 3: there's definitely a risk and potential for harm there. Yeah.
- 55:48Speaker 1: An interesting part of your describing the protocol is that
- 55:54Speaker 1: the headlines will say psychedelics secure p PTSD, but the
- 55:58Speaker 1: headlines should say psychedelics plus a very specific psychotherapy protocol
- 56:03Speaker 1: helped to reduce PTSD. Symptoms because it's not just like
- 56:06Speaker 1: they just throw psychedelics at these people and they walk
- 56:09Speaker 1: away and come back. It's a very specific human interaction
- 56:14Speaker 1: with a expert clinician therapist who is there and also
- 56:20Speaker 1: thereafter to actually integrate this stuff. And of course that's
- 56:24Speaker 1: what they found with you know SSRIs, was that when
- 56:29Speaker 1: you combined SSRIs with psychotherapy, then that seemed to be
- 56:34Speaker 1: the magic sort of combination. And from my biology classes,
- 56:39Speaker 1: I remember the professor talking about how they originally thought, okay,
- 56:44Speaker 1: SSRIs are actually helping with the brain chemistry. But his
- 56:49Speaker 1: and maybe you know other experts, their hypothesis was the
- 56:53Speaker 1: you know, prozac and other serotonin acting substances. One hypothesis
- 57:00Speaker 1: that it opens the mind up to be changed, but
- 57:03Speaker 1: you have to actually actively try to change it through
- 57:06Speaker 1: either self reflection or through psychotherapy, and by just taking
- 57:12Speaker 1: the medication, it just sort of, you know, makes your
- 57:16Speaker 1: brain flexible to a new state, and you have to
- 57:19Speaker 1: capitalize on that flexibility in a way that's very specific,
- 57:22Speaker 1: and you can't rely on people to just come up
- 57:25Speaker 1: with that you know, new homeostasis. Naturally, there has to
- 57:31Speaker 1: be some kind of engineering to get it there. And
- 57:34Speaker 1: so that's one thing. And yeah, I mean getting to
- 57:37Speaker 1: the harm. I know anecdotally that for people who recreationally
- 57:44Speaker 1: will take psychedelics will experience trauma because of the bad
- 57:50Speaker 1: trips or you know, some other kind of effect that
- 57:55Speaker 1: was not pleasant for them. You know, it's not guaranteed
- 57:59Speaker 1: that you're going to have a great time. And and
- 58:02Speaker 1: the trip, if you know, taken normally, can last for
- 58:06Speaker 1: hours an hour, so if you get into a bad
- 58:09Speaker 1: spot like you could be in that bad spot for
- 58:11Speaker 1: a long time.
- 58:12Speaker 2: Now.
- 58:12Speaker 1: Of course, there are ways to help people that a
- 58:15Speaker 1: lot of people don't turn to when they could, or
- 58:17Speaker 1: it's not offered to them, that could definitely help. But
- 58:22Speaker 1: but you know, there is that risk. Even under a
- 58:25Speaker 1: controlled environment, it's much lower risk according to the data, right.
- 58:29Speaker 1: But the other is that you know, from my understanding
- 58:33Speaker 1: of the research, and it's hard to know exactly, but
- 58:35Speaker 1: it can trigger in a very rare case, psychosis for
- 58:40Speaker 1: some people, which can last well beyond the the you know,
- 58:46Speaker 1: the the use. So yeah, I mean it is something
- 58:50Speaker 1: to consider before going into this that what you're talking
- 58:56Speaker 1: about is a very controlled scenario that is meant to
- 59:00Speaker 1: reduce those risks absolutely.
- 59:03Speaker 3: Yeah, I mean and I think just speaking in you know,
- 59:07Speaker 3: to the general population of people who are either you know,
- 59:12Speaker 3: accessing a psychotherapist or who are a psychotherapist. One of
- 59:17Speaker 3: the things that I'm doing in my private what I
- 59:20Speaker 3: call my private practice work, but my work outside of
- 59:22Speaker 3: the research settings, is to help build programs for therapists
- 59:29Speaker 3: to become more educated about even just some of the
- 59:32Speaker 3: simple harm reduction, preparation and integration concepts that they can
- 59:40Speaker 3: use in a very basic introductory conversation with someone, because
- 59:46Speaker 3: we really feel that a lot of those harms can
- 59:49Speaker 3: be mitigated by sort of thinking some things through all
- 59:53Speaker 3: the ahead of time and afterward you mentioned, you know,
- 59:57Speaker 3: people having bad experiences oricult experiences. It can kind of
- 1:00:01Speaker 3: extend for some period of time after the acute psychedelic
- 1:00:06Speaker 3: effects should have worn off. One of the things that
- 1:00:10Speaker 3: we do in our trainings is start to educate clinicians
- 1:00:13Speaker 3: about what to look for, what to assess for, how
- 1:00:17Speaker 3: to provide verbal reassurance, how to reduce harm should they
- 1:00:22Speaker 3: see something like that, as well as what else can be,
- 1:00:27Speaker 3: you know, might they try to do for somebody who's
- 1:00:29Speaker 3: in such a situation, both from a perspective of keeping
- 1:00:33Speaker 3: them safe but also from a perspective of reducing a
- 1:00:36Speaker 3: long term any long term potential for long term negative consequences.
- 1:00:41Speaker 1: Right, Yeah, how do you both in your what you're
- 1:00:46Speaker 1: calling your private practice and the research get around the
- 1:00:51Speaker 1: legal risks and the lawsuit risks.
- 1:00:54Speaker 3: Well, in research, you know, everything that we're doing is
- 1:00:56Speaker 3: completely legal, and we're you know, we have all the
- 1:01:00Speaker 3: relevant approvals from the FDA and the DEA, and it's
- 1:01:05Speaker 3: not illegal to do to do this research given that
- 1:01:08Speaker 3: you have the correct the correct approvals and you're following law,
- 1:01:12Speaker 3: and the law does allow for this research to be done,
- 1:01:15Speaker 3: and it always has. It just took a really long
- 1:01:19Speaker 3: time from the time that those laws were put into place,
- 1:01:22Speaker 3: the more restrictive laws that we have now, which really
- 1:01:25Speaker 3: went into place in the nineteen early nineteen sixties in
- 1:01:30Speaker 3: order to protect the public from from you know, unscrupulous
- 1:01:34Speaker 3: use of drugs without proper proper research data, to researchers
- 1:01:41Speaker 3: with psychedelics being able to meet those standards and conduct
- 1:01:45Speaker 3: approved research studies. So all of that is being followed
- 1:01:49Speaker 3: in the research work is completely above above board. In
- 1:01:53Speaker 3: terms of other work, you know, in private practice with people,
- 1:01:56Speaker 3: I work from a harm reduction perspective. I don't for
- 1:02:00Speaker 3: anyone for psychedelic therapy underground. I don't refer people to
- 1:02:05Speaker 3: retreat centers that are offering psychedelics or in any way, uh,
- 1:02:11Speaker 3: you know, offer or indicate or recommend or suggest or
- 1:02:14Speaker 3: anything like that, because my position is that you know,
- 1:02:19Speaker 3: if this is a decision that someone wants to make,
- 1:02:21Speaker 3: that that's it's it's their decision. But I can It's
- 1:02:25Speaker 3: not something that I can recommend as their healthcare provider.
- 1:02:29Speaker 3: A couple of things I can do our refer people
- 1:02:33Speaker 3: to clinical trials and you know, tell them of educate
- 1:02:38Speaker 3: them about what trials are available in their area and
- 1:02:41Speaker 3: what it might mean to be able to participate in one.
- 1:02:45Speaker 3: I also can can recommend and work with people to
- 1:02:49Speaker 3: have ketemine experiences, which are available legally through through m
- 1:02:56Speaker 3: D providers that provide kedemine infusions, and a lot of
- 1:02:59Speaker 3: the same principles of psychedelic assistant therapy can be used
- 1:03:05Speaker 3: around before and after ketemine experience and if people you
- 1:03:12Speaker 3: know have gone gone to take or going to take
- 1:03:16Speaker 3: a psychedelic of their own accord in another setting, I
- 1:03:21Speaker 3: can work with them to reduce the potential for harm
- 1:03:24Speaker 3: surrounding that experience or to integrate the insights that they
- 1:03:27Speaker 3: have from that experience. And that's really where where private
- 1:03:32Speaker 3: practice work is at and what we are teaching therapists
- 1:03:36Speaker 3: to be able to begin to do in their own work.
- 1:03:39Speaker 1: So by harm reduction, I'm guessing what you are referring
- 1:03:43Speaker 1: to is someone knows that you are open to discussing
- 1:03:49Speaker 1: the use of psychedelics recreationally, not prescribed by you at
- 1:03:53Speaker 1: all and not recommended by you, but they know that
- 1:03:57Speaker 1: you're you know, that's your focus, and they say, Okay,
- 1:04:03Speaker 1: you know this therapist is open to this and I
- 1:04:06Speaker 1: want to explore this. She knows the research and they
- 1:04:12Speaker 1: you know, I guess technically speaking, recreationally, but they're trying
- 1:04:17Speaker 1: to do something with it. They're trying to reduce their depression,
- 1:04:20Speaker 1: they're trying to address their addiction, they're trying to help
- 1:04:24Speaker 1: with some trauma or something or some other issue, and
- 1:04:27Speaker 1: they will take the psychedelic on their own, and then
- 1:04:34Speaker 1: in the sessions with you, you will help them to
- 1:04:38Speaker 1: reduce harm by maybe helping them set up these environments
- 1:04:43Speaker 1: at home so that they aren't at risk of having
- 1:04:46Speaker 1: bad trips in this kind of thing and or integrating
- 1:04:51Speaker 1: the experience afterwards for the benefit of whatever goal they're
- 1:04:56Speaker 1: trying to work on it.
- 1:04:57Speaker 2: Do I have this right?
- 1:04:58Speaker 3: Yeah? I mean that's it's a fairly good description of it.
- 1:05:01Speaker 3: I Mean, what's one of the things it's always important
- 1:05:04Speaker 3: to convey to people is that there is no, uh,
- 1:05:09Speaker 3: there's no way that we can or would be reproducing
- 1:05:13Speaker 3: what happens in the research, because what we're doing is
- 1:05:19Speaker 3: you know, harm reduction around them having you know, making
- 1:05:23Speaker 3: their decision to have their own experience as opposed to
- 1:05:27Speaker 3: engaging them in psychedelic assisted therapy. But I think that there's, uh,
- 1:05:33Speaker 3: there's a lot that can be done as far as
- 1:05:36Speaker 3: helping people to you know, make balanced decisions, consider the
- 1:05:42Speaker 3: risks and benefits of deciding either way about something, maybe
- 1:05:45Speaker 3: considering alternatives, maybe getting educated about ways to keep themselves safe,
- 1:05:54Speaker 3: or about you know, potential backup plans, safety plans and
- 1:06:00Speaker 3: things like that. So there is actually quite a lot
- 1:06:03Speaker 3: that quite a lot that can be done there. And
- 1:06:06Speaker 3: you know, I think that for people who for people
- 1:06:11Speaker 3: who understand and want to sort of make their own
- 1:06:15Speaker 3: autonomous decision, that a harm reduction therapy approach is extremely helpful.
- 1:06:23Speaker 3: Our harm reduction background comes really through doctor Andrew Titarski
- 1:06:27Speaker 3: and the Center for Optimal Living in New York, a
- 1:06:31Speaker 3: place that my business partner and I worked for several
- 1:06:34Speaker 3: years and received some training and supervision. And his model
- 1:06:37Speaker 3: is called integrative harm reduction psychotherapy, and it really integrates
- 1:06:41Speaker 3: psychodynamic therapy principles with harm reduction and mindfulness and other
- 1:06:49Speaker 3: ways of supporting people in examining their relationship to a
- 1:06:54Speaker 3: substance or drug that they might use or consider using,
- 1:06:59Speaker 3: as well as bringing the relationship with the therapist into
- 1:07:02Speaker 3: the picture for support and guidance and building the client's
- 1:07:08Speaker 3: autonomy around their own decisions.
- 1:07:10Speaker 1: And for those who don't know what harm reduction is
- 1:07:13Speaker 1: in general, if I might quickly summarize it from my
- 1:07:17Speaker 1: understanding is that for a long time in the chemical
- 1:07:20Speaker 1: dependency world, abstinence was the recommendation and for many people
- 1:07:26Speaker 1: the only answer to having a life that wasn't without troubles.
- 1:07:32Speaker 1: And then harm reduction came along and said, okay, yeah,
- 1:07:35Speaker 1: abstinence can be very helpful to a lot of people.
- 1:07:38Speaker 1: But for some people this other model of not necessarily
- 1:07:46Speaker 1: accepting that abstinence is the only answer that maybe talking
- 1:07:51Speaker 1: openly about the substance use and its effects and reducing harm.
- 1:07:57Speaker 1: Maybe it's through moderation, maybe it's through the circumstances under
- 1:08:01Speaker 1: which you use, or even the specific substances you use. UH.
- 1:08:06Speaker 1: And there's there has been traditionally tremendous controversy in a
- 1:08:11Speaker 1: chemical dependency world between these two camps, because for the
- 1:08:15Speaker 1: abstinence only camp, this is perceived by some to be
- 1:08:21Speaker 1: just an excuse for addicts to continue to use and
- 1:08:25Speaker 1: to uh play around with their lives in some ways,
- 1:08:31Speaker 1: whereas harm reduction people are just trying to look at
- 1:08:35Speaker 1: you know, when they look at the data, and they're
- 1:08:36Speaker 1: just trying to be more realistic about uh for for
- 1:08:41Speaker 1: some people, not only because for some people it's really
- 1:08:44Speaker 1: hard for them to quit, but for some people it's
- 1:08:46Speaker 1: it's actually not a problem for them to you know, overall,
- 1:08:50Speaker 1: to use occasionally.
- 1:08:52Speaker 2: It's you know, obviously individual basis.
- 1:08:55Speaker 1: But but that's what harm reduction the field, you know,
- 1:08:59Speaker 1: and generally is how do you think about malpractice? You know,
- 1:09:05Speaker 1: as a fellow practicing clinician and as someone who supervises
- 1:09:10Speaker 1: a lot of paranoid supervises and trains a lot of
- 1:09:13Speaker 1: paranoid trainees, I imagine a lot of listeners are like, wait
- 1:09:17Speaker 1: a second, like, how do you I mean, I'm worried
- 1:09:20Speaker 1: about losing my license if I if I accept a
- 1:09:23Speaker 1: gift from a client for crying out loud, like this
- 1:09:26Speaker 1: woman's like supervising these people using drugs, you know, like LSD, Like,
- 1:09:30Speaker 1: holy crap, what do you do?
- 1:09:33Speaker 3: Well? Well, first of all, one thing, I cleared all
- 1:09:35Speaker 3: of my patients in private practice. And I'll just iterate
- 1:09:41Speaker 3: right now that my private practice is tiny, tiny, tiny
- 1:09:45Speaker 3: at this point, just because of so much teaching and
- 1:09:48Speaker 3: training and research responsibilities. But I, you know, I initially
- 1:09:53Speaker 3: learned and trained in a harm reduction model. This is
- 1:09:58Speaker 3: going back, they want to say, an embarrassing number of
- 1:10:01Speaker 3: years a while ago. But I, you know, right since
- 1:10:08Speaker 3: the beginning of even my you know, uh master's level
- 1:10:13Speaker 3: clinical hours, and you know, beginning going into my before
- 1:10:19Speaker 3: I was even going into my pH d program, was
- 1:10:23Speaker 3: you know, was I was thinking about ways and practicing
- 1:10:28Speaker 3: training and environments where harm reduction was supported and welcomed
- 1:10:33Speaker 3: and used, and so right off the bat was working
- 1:10:39Speaker 3: with and comfortable working with people who were not necessarily
- 1:10:42Speaker 3: abstinent from all drugs and alcohol as a prerequisite requirement
- 1:10:45Speaker 3: to be in therapy. And you know, so in a way,
- 1:10:51Speaker 3: this is is not a departure from that. The same
- 1:10:53Speaker 3: way that I wouldn't necessarily kick a patient out of
- 1:10:57Speaker 3: my psychotherapy practice because they went out on a Friday
- 1:11:01Speaker 3: night and used some cocaine, Nor would I kick someone
- 1:11:05Speaker 3: out of my psychotherapy practice if they came back from
- 1:11:08Speaker 3: an ayahuasca retreat. Right, There's a there's a parallel there,
- 1:11:13Speaker 3: and it can be helpful to think of it that
- 1:11:15Speaker 3: way because we tend to, you know, maybe put psychedelics
- 1:11:18Speaker 3: in a different category from all other substances. But sometimes
- 1:11:22Speaker 3: it's helpled to revert to like what would what happens
- 1:11:25Speaker 3: if we just you know, switched the name out and
- 1:11:28Speaker 3: think of it as any other any other substance. And
- 1:11:31Speaker 3: from a legal standpoint, I mean, I think that's probably
- 1:11:33Speaker 3: how it's mostly would be considered. Now the decision making
- 1:11:38Speaker 3: is a little bit different around it, but uh, you know,
- 1:11:42Speaker 3: that is that is one way to uh to kind
- 1:11:44Speaker 3: of conceptualize it. I think, uh, you know, the idea
- 1:11:51Speaker 3: that people uh you know, any drug use and all
- 1:11:54Speaker 3: drug uses of any kind, psychedelic or otherwise, is is
- 1:11:58Speaker 3: bad and people shouldn't be uh, you know, we should
- 1:12:00Speaker 3: just sort of come at it with a pre pre
- 1:12:04Speaker 3: formulated idea that it shouldn't be there, and it should
- 1:12:07Speaker 3: be reduced or it should be gone in order for
- 1:12:09Speaker 3: people to be in psychotherapy is actually pretty damaging and
- 1:12:13Speaker 3: excludes a lot of people and a lot of people's
- 1:12:16Speaker 3: actual experience from from what they're able and willing to
- 1:12:21Speaker 3: talk talk about in psychotherapy. So I see it as
- 1:12:24Speaker 3: my responsibility to welcome people's experiences into my into my
- 1:12:30Speaker 3: psychotherapy sessions and be open to what they're experiencing. And
- 1:12:33Speaker 3: if my patients are telling me I think this is
- 1:12:36Speaker 3: going to be helpful for me and I want to
- 1:12:37Speaker 3: talk about it, then that's what we're going to talk about. Yeah.
- 1:12:40Speaker 1: I find that dogma is still around frustratingly that if
- 1:12:45Speaker 1: a client is actively using substances, but only in a
- 1:12:50Speaker 1: specific class, right, if they have a couple of glasses
- 1:12:52Speaker 1: of wine on Friday night, we don't exclude people, but
- 1:12:55Speaker 1: if some you know, and more. This is more in
- 1:12:58Speaker 1: the past, but I think still if they're smoking pot
- 1:13:02Speaker 1: every other day or using psychedelics every other day, somehow
- 1:13:07Speaker 1: there's this dogma in our field that it's just like, well,
- 1:13:10Speaker 1: you can't treat that person.
- 1:13:11Speaker 2: They got to work on their addiction.
- 1:13:12Speaker 1: They got to become abstinent before you can work with
- 1:13:15Speaker 1: them in psychotherapy, because therapy is like useless in that situation.
- 1:13:19Speaker 1: And I'm just like, okay, show me the research on
- 1:13:21Speaker 1: that one, because that is not supported by the science.
- 1:13:24Speaker 1: Plus it's like completely just on its face ridiculous when
- 1:13:28Speaker 1: you understand humans and you understand substances, and you've take
- 1:13:32Speaker 1: into consideration the commercial with Ben Affleck flipping out on
- 1:13:37Speaker 1: the ground having used marijuana. If you remember that commercial
- 1:13:43Speaker 1: back in the nineties, This notion of you know, substances
- 1:13:47Speaker 1: just completely change you into this like you know, substance
- 1:13:51Speaker 1: zombie or something that can't be you're just like a
- 1:13:54Speaker 1: completely different state of animal. Is just silly, And somehow
- 1:13:59Speaker 1: caffeine is off the hook, Like I said, occasional alcohol
- 1:14:02Speaker 1: use is off the hook, right.
- 1:14:04Speaker 3: I mean that kind of it's a it's a sort
- 1:14:07Speaker 3: of a pervasive idea and culture, and it's one thing
- 1:14:11Speaker 3: that it's resulted in is not very good education about
- 1:14:16Speaker 3: varieties of experiences with substance use and about psychedelics as
- 1:14:22Speaker 3: potential potential having potential healing properties in graduate education. So
- 1:14:28Speaker 3: I think it's just it's something. It's like a big
- 1:14:30Speaker 3: missing piece of a lot of therapists education. I run
- 1:14:34Speaker 3: into a lot of therapists who feel, you know, oh,
- 1:14:36Speaker 3: I can't work with addictions. I don't have that particular
- 1:14:39Speaker 3: special experience or training. I'm not in that club. I
- 1:14:43Speaker 3: don't think that's the case at all. I mean, I
- 1:14:45Speaker 3: think these are sort of varieties of human suffering, and uh,
- 1:14:50Speaker 3: there's a lot more about about all of this that's
- 1:14:52Speaker 3: universal as opposed to qualitatively different. And when I trained
- 1:14:59Speaker 3: therapists to do harm reduction integration work with psychedelics, one
- 1:15:04Speaker 3: of the main principles is really that I think, you know,
- 1:15:08Speaker 3: good therapists have a lot already on board to contribute.
- 1:15:12Speaker 3: It's not a whole different it's not a whole different
- 1:15:15Speaker 3: set of skills one would need to learn, but good
- 1:15:19Speaker 3: therapeutic technique, good rapport, good care and concern about your
- 1:15:23Speaker 3: about your clients, and openness and willing to listen to
- 1:15:25Speaker 3: their experience, and those are the basic building blocks of it.
- 1:15:33Speaker 1: Has there been any test cases in Department of Health
- 1:15:37Speaker 1: or in civil suits that involve a patient who is
- 1:15:42Speaker 1: in something similar or even your form of approach, who say,
- 1:15:50Speaker 1: attempts suicide or complete suicide, or drives while in talks gate,
- 1:15:56Speaker 1: it gets an accident, the patient or the family looks
- 1:15:59Speaker 1: into it, sues the practitioner, the clinician, accusing them of
- 1:16:05Speaker 1: approving of the substance use or encouraging it, or not
- 1:16:11Speaker 1: taking a harder stance against the substance use. For the
- 1:16:14Speaker 1: duty to protect standard, Has there been any case around
- 1:16:19Speaker 1: that because I could see something like that, I could
- 1:16:20Speaker 1: see a family or an individual making that claim.
- 1:16:24Speaker 3: What I can say is that, you know, I'm not
- 1:16:25Speaker 3: familiar with all of the case law around all of
- 1:16:28Speaker 3: what has transpired with all the harm reduction cases and
- 1:16:32Speaker 3: people in harm reduction therapy. You know, certainly it does
- 1:16:37Speaker 3: happen when when in the unfortunate case, when someone who's
- 1:16:42Speaker 3: in therapy or in treatment complete suicide or has some
- 1:16:46Speaker 3: other really adverse outcome, that there can be lawsuits. It
- 1:16:51Speaker 3: does happen. But harm reduction psychotherapy in general and as
- 1:16:58Speaker 3: an approach to working with addictive behaviors is certainly well
- 1:17:01Speaker 3: established and certainly stands its ground as a recognized and
- 1:17:07Speaker 3: valued and widely practiced approach.
- 1:17:10Speaker 1: Right, Thus the standard of care defense stands. But it is,
- 1:17:15Speaker 1: but it is different, at least from my understanding of
- 1:17:19Speaker 1: what you're talking about. You know, someone comes in and says,
- 1:17:23Speaker 1: and I get the I don't know the protective factor
- 1:17:28Speaker 1: of saying, look, we're working within the harm reduction model,
- 1:17:32Speaker 1: which I think is valid, but philosophically it feels different
- 1:17:37Speaker 1: to me enough at least to provide the potential for
- 1:17:44Speaker 1: you know, hostile lawyers, so to speak, to to find
- 1:17:48Speaker 1: that crack in that when when someone comes in and
- 1:17:52Speaker 1: they're like, look, I've been struggling with alcohol use on
- 1:17:56Speaker 1: and off in my life and I've tried a a
- 1:17:59Speaker 1: I've tried abstinence, it doesn't really work. I want to
- 1:18:03Speaker 1: I want to try a new approaching and say, oh,
- 1:18:05Speaker 1: well there's harm reduction.
- 1:18:06Speaker 2: Okay.
- 1:18:06Speaker 1: So you have these conversations with them about like, how
- 1:18:10Speaker 1: can you, you know, use a little bit but not
- 1:18:16Speaker 1: so much that you're causing tremendous harm in your life,
- 1:18:19Speaker 1: and maybe there's some side effects like you're a little
- 1:18:24Speaker 1: tired the next day, or you can't do work while
- 1:18:27Speaker 1: you have a few glasses of wine two times a
- 1:18:30Speaker 1: week or something, so that you know there's it's not
- 1:18:33Speaker 1: without its negative consequences, but you get the benefit of
- 1:18:36Speaker 1: the fact that you're not white knuckling it. You're not
- 1:18:39Speaker 1: you know, shaming yourself for quote unquote relapsing. And you know,
- 1:18:43Speaker 1: there's all these kinds of voice. So you know, it's
- 1:18:46Speaker 1: a kind of a very simplistic harm reduction example.
- 1:18:50Speaker 2: But what you're talking about is different.
- 1:18:53Speaker 1: You're talking about Okay, you're using you know, psychedelics. Obviously,
- 1:18:59Speaker 1: I'm not going to dictate your life, and you know,
- 1:19:04Speaker 1: what kind of approach do you want to have when
- 1:19:05Speaker 1: the person's like, well, I want to occasionally use and
- 1:19:07Speaker 1: I want to talk about it with you as a
- 1:19:10Speaker 1: way of integrating those experiences as to better my life
- 1:19:15Speaker 1: in one way or another. And so you're in a
- 1:19:19Speaker 1: sense it's at least perceived by the client that this
- 1:19:23Speaker 1: psychedelic usage outside of therapy is in essence and adjunct
- 1:19:29Speaker 1: to therapy. So to me, it is philosophically different. I
- 1:19:34Speaker 1: do respect and would defend the you know, the usage
- 1:19:39Speaker 1: of the harm reduction umbrella standard because I do think
- 1:19:43Speaker 1: it does apply in an essence, but it is kind
- 1:19:45Speaker 1: of different, don't you think it's I see.
- 1:19:48Speaker 3: It as an extension of the underlying harm reduction principles,
- 1:19:53Speaker 3: and maybe actually a selection of them. But one thing
- 1:19:58Speaker 3: that might also be helpful to consider is what would
- 1:20:02Speaker 3: what would be the opposite, right, So the opposite might be,
- 1:20:07Speaker 3: you know, not providing any psycho education. Uh you know,
- 1:20:15Speaker 3: you know, telling the person this is not something you
- 1:20:17Speaker 3: should do, really like, making a very clear uh you know,
- 1:20:22Speaker 3: taking a very clear, prohibitive stance about it. And from
- 1:20:27Speaker 3: our perspective, that has the potential to actually do harm, right,
- 1:20:32Speaker 3: because then they're less likely to learn ways to protect themselves,
- 1:20:37Speaker 3: They're less likely to engage in a really thoughtful consideration
- 1:20:43Speaker 3: of it, or engage in some really balanced decision making,
- 1:20:48Speaker 3: and that has the potential to actually sort of increase
- 1:20:52Speaker 3: the harms of not just stigma and isolation, but lack
- 1:20:55Speaker 3: of information that can that can enhance the risks. So,
- 1:21:01Speaker 3: I mean, I feel much better that I'm able to
- 1:21:06Speaker 3: provide people with some uh some education and some ways
- 1:21:11Speaker 3: of making a making a more suitable decision, as opposed
- 1:21:15Speaker 3: to just coming out as from a prohibitive stance, which
- 1:21:19Speaker 3: is probably going to put them in a place where
- 1:21:23Speaker 3: they're less likely to be able to take care of themselves.
- 1:21:25Speaker 1: Yeah, and you know, I don't want to hammer on
- 1:21:28Speaker 1: this too much. But I just find that for me
- 1:21:32Speaker 1: since I don't do this work, I uh, and I
- 1:21:36Speaker 1: tend to rail against society in these ways.
- 1:21:40Speaker 2: You know, if.
- 1:21:40Speaker 1: Someone said, I'm I want to talk about going hiking
- 1:21:45Speaker 1: once a week and how those experiences are helping me
- 1:21:49Speaker 1: with my goals in therapy, and so, therapist, can you
- 1:21:53Speaker 1: you're a you're a hike focused therapist. I you know,
- 1:21:58Speaker 1: every session, I'm going to talk about my hike that
- 1:22:01Speaker 1: I went on on Sunday, and I'm going to talk
- 1:22:03Speaker 1: about how, you know, I thought about this and I
- 1:22:08Speaker 1: ran into these people and I saw a elk and
- 1:22:12Speaker 1: it just helped me in this way. And I I
- 1:22:15Speaker 1: meditated on the death of my parents and and you know,
- 1:22:19Speaker 1: I want to talk about that. You know, we don't
- 1:22:22Speaker 1: have to frame that in a harm reduction model, right,
- 1:22:27Speaker 1: We're just like, great, you know, your life is your life.
- 1:22:30Speaker 1: Are there risks to hiking? Yeah, but I don't have
- 1:22:34Speaker 1: I'm not in the business of telling people what to
- 1:22:38Speaker 1: do or telling people how to live their lives.
- 1:22:40Speaker 2: So you know, do you know the risks Fella?
- 1:22:43Speaker 1: Yeah, I know they're Okay, fine, you know, let's talk
- 1:22:45Speaker 1: about it somehow. When it comes to psychedelic exploration for people.
- 1:22:49Speaker 1: We have to frame it in this this way in
- 1:22:54Speaker 1: which it at least gives the impression or you know,
- 1:22:58Speaker 1: the very you know, real action of us, you know,
- 1:23:03Speaker 1: cautioning people against the ill effects of the substance, even
- 1:23:07Speaker 1: though it's an adult doing something, you know what I.
- 1:23:09Speaker 3: Mean, I mean absolutely, and that's something that is very well,
- 1:23:13Speaker 3: I think, very thoroughly discussed and very openly discussed in
- 1:23:16Speaker 3: the harm reduction psychotherapy setting and certainly documented that it's discussed.
- 1:23:22Speaker 3: But you know, one thing that might help to mention
- 1:23:25Speaker 3: is that oftentimes when people come to us with questions
- 1:23:28Speaker 3: about doing is not actually illegal. People are coming to
- 1:23:32Speaker 3: us with questions about you know, for instance, taking a
- 1:23:35Speaker 3: psychedelic that is would mean going abroad to take it
- 1:23:39Speaker 3: in a you know, in a retreat setting where it's
- 1:23:41Speaker 3: simply unregulated or it's uh legal but not actually a
- 1:23:45Speaker 3: medical use situation. So there's a lot of sort of
- 1:23:48Speaker 3: gray areas around that that we can help people to
- 1:23:52Speaker 3: understand what that what that means, you know, what does
- 1:23:56Speaker 3: it mean to go somewhere where this particular compound is
- 1:23:59Speaker 3: not regulated and what might they expect also to help evaluate,
- 1:24:03Speaker 3: you know, the other people that might be providing it
- 1:24:06Speaker 3: to them and might be there with them during the
- 1:24:08Speaker 3: UH during said experience. We do a lot of educating
- 1:24:11Speaker 3: about alternatives, especially because of the media. Like you mentioned before,
- 1:24:15Speaker 3: people will sometimes come in really with the idea that
- 1:24:18Speaker 3: this is the only thing that would help them, and
- 1:24:24Speaker 3: you know, I consider it a successful discussion when someone
- 1:24:28Speaker 3: leaves with, you know, an idea about some of the
- 1:24:32Speaker 3: other options and alternatives that might be out there for them.
- 1:24:35Speaker 3: One of the things that I'm really invested in studying
- 1:24:38Speaker 3: and I'm practicing myself certainly, is work with other methods
- 1:24:45Speaker 3: for accessing alternative states of consciousness, So non drug methods
- 1:24:49Speaker 3: such as meditation, yoga, breath work, you know, UH, sensory deprivation,
- 1:24:55Speaker 3: all kinds of other things that can really give people
- 1:24:58Speaker 3: a lot of what they are seeking without the actual
- 1:25:03Speaker 3: psychedelic compound. So there's just a lot of variety that
- 1:25:06Speaker 3: can go into that conversation. It can really open up
- 1:25:09Speaker 3: the possibilities for people.
- 1:25:10Speaker 1: So my last question for you, Elizabeth is why did
- 1:25:13Speaker 1: you choose this as a focus in your career.
- 1:25:15Speaker 2: I mean, it's certainly.
- 1:25:18Speaker 1: An interesting area to look into, and you seem passionate
- 1:25:22Speaker 1: about it.
- 1:25:22Speaker 2: Why did you choose this absolutely.
- 1:25:24Speaker 3: I come from a community where knowledge about the psychedelic
- 1:25:29Speaker 3: history was fairly well distributed. It was fairly well known,
- 1:25:34Speaker 3: so it wasn't a mystery to me. I think a
- 1:25:37Speaker 3: lot of people were unaware of what happened in the
- 1:25:40Speaker 3: nineteen fifties and sixties and the whole you know, surge
- 1:25:44Speaker 3: of LSD research and Timothy Leary and prohibition and all
- 1:25:48Speaker 3: of that. But I was well aware of that, and
- 1:25:52Speaker 3: when I went to graduate school, I was actually surprised
- 1:25:55Speaker 3: that I heard virtually nothing about it. I knew that,
- 1:26:01Speaker 3: you know, psychedelic research had stopped, and psychedelics obviously were
- 1:26:04Speaker 3: not available legally, but it was sort of during this
- 1:26:08Speaker 3: period of not much going on. Maybe a few studies
- 1:26:14Speaker 3: had restarted, but they were so small and obscure that
- 1:26:17Speaker 3: I certainly had no way of hearing about them until
- 1:26:22Speaker 3: I was just a few months away from defending my dissertation.
- 1:26:27Speaker 3: My doctoral dissertation, and I had studied a lot of
- 1:26:32Speaker 3: different approaches to working with addictions and harm reduction and
- 1:26:38Speaker 3: mindfulness based approaches, a lot of things that were in
- 1:26:41Speaker 3: some way related, but I didn't quite have the full
- 1:26:44Speaker 3: picture yet. And I received an email through my state
- 1:26:50Speaker 3: Psychological Association list serve, which if every therapist is not
- 1:26:56Speaker 3: already connected with your state psychological association or or similar group,
- 1:27:01Speaker 3: this is a real reason to be A local institution
- 1:27:06Speaker 3: was looking for someone to join a study as a therapist,
- 1:27:13Speaker 3: and it was very clearly a psilocybin assisted treatment study,
- 1:27:17Speaker 3: and they were looking for a lot of the things
- 1:27:19Speaker 3: that I had on my you know, checked off on
- 1:27:22Speaker 3: my years of experience, and it just seemed like the
- 1:27:25Speaker 3: perfect fit. It was like an immediate cliq for me.
- 1:27:28Speaker 3: This makes perfect sense. Yes, I was like, where have
- 1:27:32Speaker 3: these people been? I'm so glad that this is happening.
- 1:27:37Speaker 3: And I went in. I called them up, and I
- 1:27:40Speaker 3: went over and had an interview, and the team you
- 1:27:45Speaker 3: know was, uh, was really happy to work with me.
- 1:27:48Speaker 3: We we kind of hit it off right away, and
- 1:27:51Speaker 3: from there it was just a long slow process of
- 1:27:54Speaker 3: patients and training and returning and returning and you know,
- 1:27:59Speaker 3: keeping on with all kinds of different requirements and credentials
- 1:28:03Speaker 3: and uh you know, institutional trainings and specific research trainings
- 1:28:08Speaker 3: and to eventually be able to build this is you know,
- 1:28:13Speaker 3: six years later, a really full full fledged, full time
- 1:28:18Speaker 3: career in both clinical research, private practice and education. So
- 1:28:24Speaker 3: I know that there are a lot of people out
- 1:28:25Speaker 3: there that are really really interested in this field. I
- 1:28:29Speaker 3: have to say if you if you want to go
- 1:28:31Speaker 3: into research, make sure that you actually want to go
- 1:28:33Speaker 3: into research, because the world of clinical research has its
- 1:28:36Speaker 3: own whole set of regulations and requirements and things that
- 1:28:40Speaker 3: you need to learn and know about, and they're fascinating
- 1:28:43Speaker 3: if you've got that particular type of nerd hat. But
- 1:28:47Speaker 3: if it's something that you're more interested in from a
- 1:28:50Speaker 3: psychotherapist's perspective, I think now is the time to start
- 1:28:53Speaker 3: getting some training in psychedelic harm reduction and integration, start
- 1:28:57Speaker 3: having you know, conversations with peopleeople who've used psychedelics in
- 1:29:01Speaker 3: your practice, just so you get a feel for what
- 1:29:03Speaker 3: that's like. And in the next couple of years, there
- 1:29:06Speaker 3: are going to be more and more opportunities, you know,
- 1:29:09Speaker 3: pending the research moving forward in the direction that we expect,
- 1:29:14Speaker 3: there's going to be more and more opportunities for people
- 1:29:16Speaker 3: to get training actually in psychedelic assisted therapy and how
- 1:29:20Speaker 3: to administer and how to really be there with people
- 1:29:22Speaker 3: during that experience. But those training opportunities are not really
- 1:29:26Speaker 3: online yet because there's no opportunity to use that kind
- 1:29:33Speaker 3: of training in private practice quite yet at this time, Well.
- 1:29:37Speaker 1: You must be naturally and out of the box, unafraid, thinker,
- 1:29:41Speaker 1: and liver, because most people, having faced with that opportunity, would,
- 1:29:48Speaker 1: especially at that stage of one's career where people are
- 1:29:51Speaker 1: at their most paranoid, most people would have turned it
- 1:29:55Speaker 1: down even if they wanted to do it.
- 1:29:57Speaker 2: So you know, you're a brave, courageous.
- 1:30:00Speaker 3: Oh no, I was all in, thank you, I appreciate that,
- 1:30:04Speaker 3: But I really have to say, you know, I had
- 1:30:08Speaker 3: I had the background to recognize and know what I
- 1:30:11Speaker 3: was looking at, and I'm very grateful that I did.
- 1:30:15Speaker 3: But I also had some I did get some funny looks.
- 1:30:17Speaker 3: I will, I will admit that I got some funny looks.
- 1:30:20Speaker 3: And you know, it's one thing to be able to
- 1:30:22Speaker 3: just tell people this is what I'm doing, this is
- 1:30:25Speaker 3: what I believe in, and sometimes you just have to
- 1:30:28Speaker 3: do what you believe in.
- 1:30:29Speaker 1: You say you have a background, and the thing that
- 1:30:32Speaker 1: popped into my head was the stereotype of like your
- 1:30:35Speaker 1: parents were dead heads or something. I don't know, like,
- 1:30:38Speaker 1: what do you mean by a background?
- 1:30:40Speaker 3: My parents were not quite dead heads, but my mom
- 1:30:44Speaker 3: was a bit of a hippie. She grew up in
- 1:30:47Speaker 3: New York City, and she moved to Woodstock in nineteen
- 1:30:50Speaker 3: sixty eight, which, for those unfamiliar, is about two hours
- 1:30:54Speaker 3: north of New York City, and it was sort of
- 1:30:56Speaker 3: this hippie cultural center, which gave rise to the famous
- 1:31:01Speaker 3: Woodstock Concert of nineteen sixty nine. And I grew up
- 1:31:05Speaker 3: in that community long after the heyday of the hippie years,
- 1:31:12Speaker 3: but I was definitely exposed to a lot of the
- 1:31:13Speaker 3: stories of the people of her generation. The artists and
- 1:31:17Speaker 3: the musicians that were really prominent at that time. They
- 1:31:23Speaker 3: were all still around, and they were, you know, they
- 1:31:25Speaker 3: were my parents' friends. They were like the moms and
- 1:31:28Speaker 3: dads picking us up after elementary school, and they would
- 1:31:32Speaker 3: just tell us stories about this stuff. It was no secret.
- 1:31:35Speaker 3: It was just, you know, well that's what our that's
- 1:31:38Speaker 3: what our parents' generation was up to, and we're out
- 1:31:40Speaker 3: here like normal kids, you know, playing soccer and going
- 1:31:43Speaker 3: to theater and getting off to college and trying to
- 1:31:46Speaker 3: figure out what we're doing with our lives. But I
- 1:31:49Speaker 3: think that the stories of that generation were definitely sort
- 1:31:52Speaker 3: of baked into my community.
- 1:31:55Speaker 2: Wow, it's interesting. I didn't know that.
- 1:31:57Speaker 1: I mean, of course knew about what's Stock, but I
- 1:32:00Speaker 1: ever knew why they chose Woodstock. I thought it was
- 1:32:02Speaker 1: just a convenient campground or a you know, festival ground
- 1:32:07Speaker 1: for them to have the festival. I didn't know that
- 1:32:10Speaker 1: it had already become kind of a New York hippie bastion.
- 1:32:16Speaker 3: Oh yeah, it was. It was actually always a colony
- 1:32:19Speaker 3: of the arts for years, even many years before that,
- 1:32:23Speaker 3: because artists from New York City would come up, and
- 1:32:26Speaker 3: the Art Students League had its summer school there, and
- 1:32:29Speaker 3: there were all these like artists cottages where sculptors and
- 1:32:32Speaker 3: painters and musicians would come up and spend the summer
- 1:32:34Speaker 3: in the mountains. And that had been well established for
- 1:32:37Speaker 3: many years. And then in the nineteen sixties, the you know,
- 1:32:42Speaker 3: so the folk musicians and Bob Dylan and the hippies
- 1:32:44Speaker 3: started showing up, and it was already established as that.
- 1:32:49Speaker 3: And the Woodstock Festival was named for the town because
- 1:32:51Speaker 3: the organizers and most of the many of the musicians
- 1:32:54Speaker 3: had a relationship to that to that town. But the
- 1:32:57Speaker 3: festival was actually held in another part of the in
- 1:33:01Speaker 3: another county, you know, like a fifty or sixty minute
- 1:33:04Speaker 3: drive away. It was. It was not actually in town.
- 1:33:07Speaker 2: Oh really interesting.
- 1:33:08Speaker 1: Yeah, So any famous names that you can drop here,
- 1:33:12Speaker 1: you know, you said, you know the musicians where you're
- 1:33:17Speaker 1: you know, the other parents in the community.
- 1:33:19Speaker 3: M hm, Well, if you're familiar with For those familiar
- 1:33:25Speaker 3: with Bob Dylan, you know, he lived in Woodstock for
- 1:33:28Speaker 3: a very long time. The band that was the band
- 1:33:32Speaker 3: that played with him named the band, many of they
- 1:33:37Speaker 3: lived in Woodstock for quite a long time, and many
- 1:33:39Speaker 3: of them remained there over the years. We're good friends
- 1:33:44Speaker 3: with my mom and her family, and just a lot
- 1:33:47Speaker 3: of a lot of people from town, a lot of
- 1:33:49Speaker 3: artists and and other you know, other musicians that lived there.
- 1:33:55Speaker 3: Certainly the town is famous for having uh, you know,
- 1:34:00Speaker 3: tended visits or residences from Jenas Choplin and Jimi Hendrix,
- 1:34:04Speaker 3: people that came through the area. But it was pretty
- 1:34:08Speaker 3: well well frequented.
- 1:34:10Speaker 2: Yeah, I mean, it's just a perfect story.
- 1:34:12Speaker 1: You know, the kid from Woodstock becomes a psychologist and.
- 1:34:18Speaker 2: By the community.
- 1:34:19Speaker 3: It was, oddly enough, it wasn't my goal to get
- 1:34:21Speaker 3: involved in psychedelic therapy. I didn't even know it would
- 1:34:24Speaker 3: be an option by the time I got that far.
- 1:34:27Speaker 3: You know, fifteen years out into adulthood and you know,
- 1:34:31Speaker 3: it sort of just landed on my landed in my inbox.
- 1:34:35Speaker 3: But so it's a bit of a coincidence, but definitely
- 1:34:39Speaker 3: not a not a far fetched thing for me.
- 1:34:43Speaker 1: Yeah, if I mean, I think Timothy Leary was at Woodstock,
- 1:34:47Speaker 1: if I'm not mistaken, or at least his disciples would
- 1:34:51Speaker 1: have been right. And to think that if they only
- 1:34:54Speaker 1: would have known that a local, you know, psychologist person
- 1:35:00Speaker 1: and would end up carrying the torch and doing the
- 1:35:03Speaker 1: cause and making it making it legit.
- 1:35:06Speaker 2: Absolutely, Yeah, that's pretty what a.
- 1:35:09Speaker 3: Lot of people don't might not know, is it.
- 1:35:11Speaker 1: Leary was a psychologist, yeah, and a professor at Stanford Harvard.
- 1:35:15Speaker 3: He had a fascinating career, fascinating life. Really one of
- 1:35:18Speaker 3: my favorite topics in history, and it's a lot of
- 1:35:22Speaker 3: fun to read about. But his mansion in the nineteen
- 1:35:26Speaker 3: sixties after he left Harvard, his mansion was actually in Millbrook,
- 1:35:31Speaker 3: New York, which is about forty five minute drive south
- 1:35:36Speaker 3: of Woodstock, So he was in the area, but he
- 1:35:38Speaker 3: wasn't actually living in town.
- 1:35:40Speaker 1: Didn't he spend time in prison because of his advocacy
- 1:35:43Speaker 1: in the sixties.
- 1:35:43Speaker 3: Absolutely, Yeah, he was in he was in prison. He
- 1:35:47Speaker 3: was in jail in California. He escaped and he was.
- 1:35:54Speaker 2: He escaped from prison.
- 1:35:55Speaker 3: Yeah, he escaped from from prison in California, and then
- 1:35:59Speaker 3: he was recapped sured somewhere in Europe. And I apologize
- 1:36:04Speaker 3: that I don't have the story so fresh in my mind,
- 1:36:06Speaker 3: but he was recaptured. Nixon was very determined to bring
- 1:36:11Speaker 3: him back and get him back into prison, and he
- 1:36:16Speaker 3: actually served quite a substantial amount of time in solitary confinement.
- 1:36:21Speaker 3: He was at Harvard for about two years, and while
- 1:36:25Speaker 3: he was there, he specifically, you know, decided to make
- 1:36:28Speaker 3: psilocybin and LSD research his main the main focus of
- 1:36:32Speaker 3: his interest and conduct research with those drugs while he
- 1:36:36Speaker 3: was there. But it was really after he left Harvard
- 1:36:42Speaker 3: that he became sort of this outspoken advocate for widespread
- 1:36:47Speaker 3: LSD use. But he certainly had a He had an
- 1:36:52Speaker 3: extremely interesting life, and I mean much has been written
- 1:36:55Speaker 3: about it, and I think we're starting to understand things
- 1:36:57Speaker 3: a little bit better in uh in perspective, but I
- 1:37:00Speaker 3: feel for years he was sort of scapegoaded, as you
- 1:37:03Speaker 3: know the reason that psychedelics were prohibited, But history actually
- 1:37:07Speaker 3: indicates that you know there there were multiple factors that
- 1:37:12Speaker 3: contributed to that, and you know, his sort of outlandish,
- 1:37:18Speaker 3: outspoken nature made him like a sensationalized character who it's
- 1:37:25Speaker 3: easy to sort of pinpoint as you know, it was
- 1:37:28Speaker 3: it was this guy's fault, but he actually contributed quite
- 1:37:32Speaker 3: a lot to the cause for for LSD and was
- 1:37:35Speaker 3: pretty well respected by a lot of people.
- 1:37:37Speaker 1: Still is did Was he the one who said tune in,
- 1:37:40Speaker 1: turn on, drop out?
- 1:37:41Speaker 3: Yep? That was him. Yeah, he also said he also
- 1:37:44Speaker 3: said something to the effect of ELISTI has the remarkable
- 1:37:47Speaker 3: capacity to cause great, great panic and people who've never
- 1:37:53Speaker 3: taken it interesting.
- 1:37:55Speaker 2: Well, Elizabeth has been fascinating.
- 1:37:58Speaker 1: We branched off into a lot of areas that I
- 1:38:00Speaker 1: didn't expect to and you certainly seem like a very
- 1:38:04Speaker 1: responsible science communicator, which I appreciate greatly.
- 1:38:10Speaker 2: And it's an exciting field.
- 1:38:12Speaker 1: Where can people find you, not only as a therapist clinician,
- 1:38:19Speaker 1: but also as a trainer and as a maybe an
- 1:38:22Speaker 1: advisor for people wanting to get into the research.
- 1:38:25Speaker 2: How can they find you?
- 1:38:26Speaker 3: The best way to find me is through my website,
- 1:38:29Speaker 3: which is the name of my training and education program
- 1:38:33Speaker 3: is Fluence and the website is Fluence eight. That's the
- 1:38:38Speaker 3: digit eight dot com so f l U E n
- 1:38:41Speaker 3: C eight dot com. And on that website you'll find
- 1:38:46Speaker 3: a lot of information about different training programs. There is
- 1:38:49Speaker 3: a form to contact us as well as an email,
- 1:38:53Speaker 3: an info email, and a phone number and all of
- 1:38:56Speaker 3: that contact stuff works that links directly to either to
- 1:39:00Speaker 3: me or to my business partner, who is doctor Imar Gorman,
- 1:39:04Speaker 3: an oother psychologist in New York who's also in the
- 1:39:06Speaker 3: research world. And we look forward to hearing from anybody
- 1:39:11Speaker 3: who's interested. It's just us right now working on this project.
- 1:39:15Speaker 3: So if you reach out, you'll hear back from one
- 1:39:19Speaker 3: of us and we'll try to get you connected to
- 1:39:22Speaker 3: whatever it is that might help meet your needs.
- 1:39:24Speaker 2: What's fluence Referring to fluence is so it's.
- 1:39:28Speaker 3: The name of our training and education project. It's the
- 1:39:31Speaker 3: root of words like confluence and influence, and it can
- 1:39:38Speaker 3: mean something like either a magical or mystical power, or
- 1:39:43Speaker 3: has something to do with the the the the measure
- 1:39:48Speaker 3: of intensity of an electrical current or the density of
- 1:39:55Speaker 3: particles and an electrical current. So it has some meanings
- 1:39:59Speaker 3: both in science and can refer to a mystical power.
- 1:40:04Speaker 3: And it's also the word that we chose just to
- 1:40:06Speaker 3: be our name.
- 1:40:07Speaker 2: Cool.
- 1:40:08Speaker 1: Well, thanks for coming on the podcast, Elizabeth Nielsen. I
- 1:40:12Speaker 1: encourage people to reach out to Elizabeth Nielsen if you
- 1:40:15Speaker 1: have more specific questions. She is offering quite a service
- 1:40:21Speaker 1: to you in that way. I know a lot of
- 1:40:24Speaker 1: you have very specific questions and want to know more,
- 1:40:28Speaker 1: and so it's great that Elizabeth is offering yourself up
- 1:40:33Speaker 1: at least to redirect you to the right answers.
- 1:40:35Speaker 2: And that's fantastic. Yeah, yeah, I.
- 1:40:38Speaker 3: Really appreciate it. And I hope your listeners have enjoyed
- 1:40:41Speaker 3: this and we'll, you know, continue their own trajectory of
- 1:40:45Speaker 3: learning about this topic. With the resources that are out there,
- 1:40:49Speaker 3: there's just so much to learn.
- 1:40:50Speaker 1: It's really fascinating, all right, And everyone out there, please
- 1:40:54Speaker 1: take care of yourself because you deserve it, you really
- 1:40:56Speaker 1: really do.
- 1:41:05Speaker 3: Su